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1.1 G protein coupled receptors 
 
G protein coupled receptors (GPCRs) represent the largest and most versatile family 
of cell-surface receptors. The GPCR superfamily makes up nearly 2% of the human genome. 
About eighthundred genes have seven transmembrane characteristics, as assessed by 
hydrophobicity plots of amino acid sequences (Vassilatis et al., 2003). Approximately half of 
these are odorant receptors and for the remaining 360, the natural ligand has been identified 
for about 210, leaving 150 so-called “orphan GPCRs” with no known ligand or function. 
 As a superfamily of integral membrane proteins, GPCRs have a very high impact 
from a therapeutic point of view. Drugs binding to these receptors are beneficial across a 
wide range of human diseases, including pain, asthma, inflammation, obesity, cancer, as well 
as cardiovascular, metabolic, gastrointestinal and various CNS diseases. Approximately 50% 
of all modern drugs are targeted to GPCRs. Interestingly, however, the majority of these 
drugs exert their effects on about only 40 GPCRs (Wise et al., 2004; Jacoby et al., 2006; 
Lagerström and Schioth, 2008). Thus, the remaining potential for drug discovery within this 
field is enormous. 
 Two major requirements define a protein to be classified as GPCR. The first is the 
existence of seven α-helical transmembrane (TM) domains and the second is the ability to 
interact with a G protein. The GPCR is able to bind a ligand from the extracellular side and 
transduce the signal via a G protein into the cell (Fredriksson et al., 2003). However, many 
GPCRs can modulate G protein-independent pathways. Therefore, the term seven 
transmembrane (7 TM) receptors would be more appropriate. Both terms are used by the 
International Union of Pharmacology Committee on Receptor Nomenclature and Drug 
Classification (NC-IUPHAR) (Foord et al., 2005). All 7 TM receptors share a common 
architecture: an extracellular amino terminus (N-term), seven α-helical TM domains that are 
connected by three extracellular (e1, e2 and e3) and three intracellular (i1, i2 and i3) loops, 
and an intracellular carboxyl terminus (C-term). Phylogenetically, GPCRs can be divided into 
six classes. 
Family I (also referred to as family A or the rhodopsin-like family) represents by far the 
largest subgroup. Family I contains receptors for odorants, small molecules such as biogenic 
amines, peptides and glycoprotein hormones. The most important structural features of 
family I GPCRs are about 20 highly conserved amino acids and a disulphide bridge between 
the first and second extracellular loop (e1 and e2). Most of the conserved residues, including 
several proline residues and a conserved DRY (aspartate, arginine and tyrosine) motif 
adjacent to TM III, are located in the cytoplasmic half of the protein. The seven α-helices 
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span the cell membrane in a counter-clockwise manner when viewed from the extracellular 
side. 
Family II or family B GPCRs are characterized by a relatively long N-terminus, 
containing several cysteine residues, which presumably form a network of disulphide 
bridges. Their morphology is similar to family I receptors, although they share only low 
sequence homology. Little is known about the exact threedimensional arrangement of the 
TM domains, but given the divergence in amino acid sequence, it is likely quite dissimilar 
from that of family I receptors. Ligands for family II GPCRs include hormones, such as 
glucagon, gonadotropin-releasing hormone and parathyroid hormone. 
Family III contains the metabotropic glutamate, the Ca2+ sensing and the γ-
aminobutyric acid (GABA) B receptors. These GPCRs possess a long N- and C-terminus. 
The ligand binding domain is located in the amino terminus, which is often described as 
being like a “venus fly trap”. Except for two cysteines in e1 and e2 that form a putative 
disulphide bridge, family III receptors do not have any of the key features that characterize 
family I and II receptors. Unique among family III GPCRs is a short and highly conserved 
third intracellular loop (i3). Although the structure of the N-terminus is well characterized, 
similar to family II receptors, little is known about the exact threedimensional arrangement of 
the TM domains. 
The smaller, less characterized GPCR families comprise family IV pheromone 
receptors, while family V includes the “frizzled” and the smoothend receptors involved in 
embryonic development and in particular cell polarity and segmentation. Finally, the cAMP 
receptors have only been found in D. discoideum, but possible expression in vertebrates has 
not yet been reported (Bockaert and Pin, 1999). 
 A breakthrough in GPCR research was the determination of a high-resolution crystal 
structure of bovine rhodopsin by Palczewski in 2000, providing the first insight into the three-
dimensional architecture of a mammalian family I receptor (Palczewski et al., 2000). More 
recently, the first crystal structure of a human GPCR, the β2-adrenoceptor (hβ2AR), was 
solved by Kobilka and co-workers (Rasmussen et al., 2007). This was possible due to 
truncation of the receptor and generation of an antibody as stabilizing element. More protein-
engineering yielded an alternative high-resolution structure of hβ2AR via construction of a 
receptor/T4-lysozyme fusion protein (Rosenbaum et al., 2007). These milestones in GPCR 
research provided the basis for other investigators to move on in the field of structural 
receptor biology. Another catecholamine receptor structure was determined for an 
engineered turkey β1AR (Warne et al., 2008) and Jaakola et al. (Jaakola et al., 2008) 
provided structural information about the human adenosine 2A receptor (hA2AR). However, 
all these GPCR structures represent the receptors in an inactive state. Thus, the next major 
challenge in GPCR crystallography will be the determination of high-resolution active-state 
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receptor structures. Currently, much progress is being made towards this goal. Recent 
structures of opsin provide insight into active receptor states without G protein or bound to a 
G protein fragment (Park et al., 2008; Scheerer et al., 2008). The information provided by the 
new GPCR crystal structures and the lessons learned were very recently discussed and 
summarized in several articles (Kobilka and Schertler, 2008; Weis and Kobilka, 2008; Mustafi 
and Palczewski, 2009). 
Nevertheless, GPCRs are dynamic in nature and crystal structures represent only 
snapshots of specific states, so in the future, X-ray crystallography will have to be 
complemented by sophisticated biophysical studies like NMR, to learn more about the 
activation process of GPCRs on an atomic level (Ratnala, 2006; Kofuku et al., 2009). In the 
meantime, it will still be necessary to combine several different classic experimental 
approaches and molecular modelling techniques to understand the processes of ligand 
binding, receptor activation and G protein/effector coupling for a given GPCR. 
 
 
1.2 GPCR signal transduction 
 
Based on our current knowledge, binding of an agonist from the extracellular side to a 
GPCR embedded in the cell membrane is followed by a conformational change. The 
resulting active state of the receptor protein then specifically interacts with a precoupled or 
free heterotrimeric G protein, consisting of a Gα-subunit and a Gβγ-heterodimer, located at 
the cytosolic side of the membrane (Fig. 1.1). The interaction of the G protein with a receptor 
in the active state leads to the release of GDP bound to inactive G protein. Subsequently, a 
ternary complex between the agonist-bound active receptor and nucleotide-free G protein is 
formed, which is however unstable and dissociates or rearranges again (Bünemann et al., 
2003). The nucleotide-free G protein can then bind GTP and a further conformational change 
occurs. In the GTP-bound state G proteins are activated. The heterotrimeric activated G 
protein complex then dissociates into GTP-bound Gα-subunit and Gβγ-dimer, which can 
influence effector proteins. 
Heterotrimeric G proteins are typically divided into four main classes: Gi/o, Gs, Gq/11 
and G12/13 based on sequence homology of their Gα-subunits (Birnbaumer, 2007). Different 
subtypes of activated Gα-subunits can selectively inhibit (Gαi/o) or stimulate (Gαs) adenylate 
cyclase (AC), activate phospholipase Cβ (Gαq/11), or interact with guanine nucleotide 
exchange factors (Gα12/13). As a consequence, the production of second messangers such as 
cyclic 3´,5´-adenosine monophosphate (cAMP), 1,2-diacylglycerol (DAG), and inositol-1,4,5-
trisphosphate (IP3) is modulated. The second messengers can induce a fast cellular 
response, such as change in intracellular ion concentrations or the regulation of enzyme 
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activity, or cause long-term effects by modulating transcription factors, thereby regulating 
gene expression. Moreover, activated Gβγ-dimers can also trigger cellular effects 
(Birnbaumer, 2007). For example, they can directly interact with phospholipase Cβ, AC or 
certain ion channels. 
 
Fig. 1.1: Gα protein activation/deactivation 
cycle after GPCR stimulation by an 
agonist. Adapted from Seifert, 2005. 
 
After modulation of effector 
proteins, the intrinsic GTPase activity of 
the Gα-subunit terminates the signal by 
cleavage of bound GTP into GDP and 
inorganic phosphate (Pi). The GDP-bound 
Gα-subunit can then re-associate with the 
Gβγ-dimer again. The inactive GDP-bound 
heterotrimeric G protein complex is 
available for another round of activation. 
Importantly, Vmax-values of 
GTPases in reconstitution systems in vitro 
are often orders of magnitude higher than 
in tissue preparations. The reason for 
these differences is the existence of GTPase-accelerating proteins. The so-called regulators 
of G protein signalling (RGS proteins) are guanine-nucleotide exchange factors (GEFs), 
which enhance the GTPase activity of Gα-subunits (Neitzel and Hepler, 2006; Willars, 2006; 
Wieland et al., 2007). This family of proteins consists of at least 20 members that can be 
divided into 3 subfamilies. All RGS proteins share a common RGS domain, which stabilizes 
the transition state of the GTP hydrolysis at the Gα-subunit. Thus, RGS proteins function as 
negative regulators of G proteins signalling in vivo. 
Continuous or repeated stimulation of a GPCR by agonist leads to a loss of cellular 
sensitivity. This desensitation process includes phosphorylation of the GPCR by G protein 
coupled receptor kinases (GRKs), followed by β-arrestin binding and uncoupling of the G 
protein. Subsequent internalization of the receptor via clathrin-coated vesicles leads to 
sorting of the receptor either back to the plasma membrane (receptor recycling) or to 
lysosomes for degradation (Hanyaloglu and von Zastrow, 2008). 
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1.3 Constitutive activity, models of GPCR activation and ligand 
classification 
 
 During the last decades, different models based on the law of mass action have been 
developed to mathematically describe the interaction of ligand (agonist), receptor and G 
protein. In the ternary complex model, binding of the agonist to the receptor is prerequisite to 
activate the G protein. However, GPCRs can be spontaneously active, a phenomenon which 
is referred to as constitutive activity (Seifert and Wenzel-Seifert, 2002). The existence of 
constitutive receptor activity resulted in the extended ternary complex (or two-state) model, 
which assumes that GPCRs isomerize from an inactive state (R) to an active state (R*), even 
in the absence of agonist (Fig. 1.2). A receptor in the R* state binds and activates G proteins, 
resulting in a cellular response. 
According to the two-state model, ligands can be classified as agonists, neutral 
antagonists and inverse agonists (Fig. 1.3). Agonists stabilize the active R* state, inverse 
agonists the inactive R state of a GPCR. Neutral antagonists do not posess intrinsic activity 
but competitively antagonize the effects of agonists and inverse agonists. Partial agonists or 
inverse agonists possess a lower efficacy towards G protein activation or inhibition, relative 
to the endogenous (full) agonist. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2: The two state model of GPCR activation. GPCRs are able to isomerize from an 
inactive state (R) to an active state (R*). Ligands are classified according to their capability of 
shifting the equilibrium to either side of both states. Adapted from Seifert, 2005. 
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A thermodynamically more complete model is the cubic ternary complex model, 
including the formation of non-signalling complexes (RG and ARG). Based on evidence that 
multiple (most likely infinite) receptor states do exist and the increasing number of novel 
GPCR-interacting proteins (GIPs) identified, those models are continuously improved 
(Kenakin, 2004). 
 
 
 
 
 
 
 
 
 
 
Fig. 1.3: Differential responses in an effector system upon binding of full agonists (■), partial 
agonists (▲), antagonists (●), partial inverse agonists (♦), and full inverse agonists (▼). 
Adapted from Seifert, 2005. 
 
Moreover, the existence of allosteric GPCR modulators and the possibility of homo- 
and hetero-oligomerization further complicate the situation. Nonetheless, the models still can 
describe most scenarios based on the simple law of mass action. The application of the 
models goes far beyond their descriptive nature. They can be used in drug discovery to 
develop ligands with clearly defined cellular effects. 
 
 
1.4 Histamine and the histamine receptor family 
 
1.4.1 Historical perspective 
 The first report of histamine (HA, 2-(1H-imidazol-4-yl)ethanamine) was its synthesis 
by Windaus and Vogt in 1908 (Windaus and Vogt, 1908). Sir Henry Dale and colleagues 
were able to isolate this amine from ergot in 1910 (Barger and Dale, 1910). In the following 
years, HA was pharmacologically characterized (Dale and Laidlaw, 1910; Dale and Laidlaw, 
1911; Dale and Laidlaw, 1919). These early studies elaborated the fundamental effects of 
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HA, such as stimulation of smooth muscles from the gut and respiratory tract, stimulation of 
cardiac contractility and induction of shock-like syndrome when injected into animals. The 
isolation from liver and lung was the first verification of HA as an endogenous substance 
(Best et al., 1927). The first compounds that blocked the action of HA in an anaphylactic 
response were identified in the 1930s (Fourneau and Bovet, 1933; Bovet and Staub, 1937). 
Some chemicals with similar activities (e. g. mepyramine or diphenhydramine) were 
introduced into the clinic for the treatment of allergic conditions. However, these prototypical 
“antihistamines” were not able to block certain HA-effects such as the stimulation of gastric 
acid secretion. Therefore, the existence of two distinct HA receptor subtypes was predicted 
(Ash and Schild, 1966). This was confirmed, when Black and co-workers developed 
burimamide, a compound that competitively antagonized HA-induced gastric acid secretion 
(Black et al., 1972). For the treatment of gastric and duodenal ulcer more potent derivatives 
were developed (Black et al., 1973; Brimblecombe et al., 1975) and have been used as 
blockbuster drugs for decades. In the early 1980s, the groups of Schwartz and Schunack 
showed that HA inhibits its own release from depolarized slices of rat cerebral cortex, an 
action that could not be blocked by known antihistaminergics (Arrang et al., 1983). A third HA 
receptor subtype was predicted and confirmed with a potent and selective agonist ((R)-α-
methylhistamine) and antagonist (thioperamide) (Arrang et al., 1988). In the 1990s, progress 
in the field of molecular biology enabled cloning of the H1R (Yamashita et al., 1991), the H2R 
(Gantz et al., 1991) and, with substantial delay, of the H3R (Lovenberg et al., 1999). At the 
turn of the millennium, Oda et al. identified and cloned the sequence of an additional HA 
receptor and termed it H4R (Oda et al., 2000). The existence of a fourth HA receptor was 
confirmed independently by other groups (Nakamura et al., 2000; Liu et al., 2001; Morse et 
al., 2001; Nguyen et al., 2001; Zhu et al., 2001; O'Reilly et al., 2002). A detailed account on 
the history of HA and its receptors is given by Parsons and Ganellin (Parsons and Ganellin, 
2006). 
 
 
1.4.2 Histamine 
HA is one of the most important local mediators and neurotransmitters. High 
concentrations of HA are found in the skin, lung, and the gastrointestinal tract. In the 
hematopoietic system, mast cells and basophils store HA in specific granules, closely 
associated with anionic proteoglycans and chondroitin-4-sulfate. In this form, it can be 
released in large amounts during degranulation in response to various immunological or non-
immunological stimuli. Alternatively, HA is liberated upon destruction of these cells or by 
chemical substances (HA liberators). In the stomach, HA is produced in enterochromaffin-like 
cells (ECL) and regulates gastric acid secretion. In the central nervous system (CNS), HA is 
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stored in vesicles of histaminergic neurons, located exclusively in the tuberomamillary 
nucleus of the posterior hypothalamus (Haas and Panula, 2003). They are involved in the 
regulation of fundamental brain functions such as sleep/wakefulness, cognition and energy 
homeostasis (Haas and Panula, 2003). However, also other cellular sources of HA have 
been discovered, in which HA is immediately released without prior storage (Dy and 
Schneider, 2004). The production of the so-called “neo-synthesized HA” is modulated by 
cytokines and was identified in hematopoietic cells, macrophages, platelets, dendritic cells, 
and T cells. 
The key enzyme for HA synthesis is L-histidine decarboxylase (HDC) (Fig. 1.4). This 
enzyme is located in the cytosol and decarboxylates the amino acid L-histidine. HDC 
requires binding of the cofactor pyridoxal-5-phosphate. The vesicular monoamine transporter 
VMAT2 is responsible for the transport of HA from the cytosol into the secretory granules 
(Kazumori et al., 2004). HA is inactivated by oxidative deamination or methylation to form 
imidazole-4-acetaldehyde and Nτ-methylhistamine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.4: Biosynthesis and metabolism of histamine. 
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These reactions are catalyzed by diamine oxidase (DAO) and histamine N-
methyltransferase (HNMT), respectively. HNMT transfers a methyl group from S-adenosyl-L-
methionine to the Nτ-nitrogen of the imidazole ring. Imidazole-4-acetaldehyde is oxidized to 
form imidazole-4-acetic acid. Imidazole-4-acetic acid and Nτ-methylhistamine are further 
metabolized to 1-ribosylimidazole-4-acetic acid and 1-methylimidazole-4-acetic acid, 
respectively. At present, it is not clear if HNMT is translocated to the plasma membrane to 
metabolize HA or if reuptake of HA occurs by means of organic cation transporters (OCT)-2 
or -3 (Ogasawara et al., 2006). The inactive metabolites are excreted into the urine. 
 
 
 
 
 
Fig. 1.5: Tautomerism of histamine in the monocationic form. 
 
HA has two basic centres and fully protonated HA is a dication: the side chain amino 
group is a strong base (pKa2 = 9.40); the imidazole ring is a weak base (pKa1 = 5.80) (Fig. 
1.5). Under physiological conditions (pH = 7.4) the monocation predominates and is the form 
most likely to be acting at histamine receptors. The imidazole ring of HA can exist in two 
tautomeric forms, with the proton on the N proximal (Nπ-H tautomer) or distal (Nτ- H 
tautomer). In aqueous solution about 80% of HA monocation is in the Nτ-H tautomeric form 
(Ganellin, 1973). 
 
 
1.4.3 Histamine receptors 
 Histamine receptors belong to family I and are classified in four subtypes: H1R, H2R, 
H3R and H4R. The average sequence homology between the subtypes is relatively low 
(~20%). H3R and H4R share the highest overall sequence homology of about 40% (~58% 
homology in the TM regions). An overview of the most important properties of histamine 
receptors is given in Table 1.1. 
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Table 1.1: Overview on histamine receptors. 
 
H1R 
Gene locus 
 
Amino acids 
 
Expression pattern 
 
 
 
Signal transduction 
(main pathways) 
 
(Patho)physiological function 
 
 
 
Agonists 
 
 
Antagonists/inverse agonists 
 
 
 
 
3p25 
 
487 
 
airway and vascular smooth muscle cells, neurons, 
hepatocytes, endothelial and epithelial cells, hematopoietic 
cells 
 
Gαq/11 → PLC↑, DAG↑ and IP3↑; [Ca
2+]↑; PKC↑ 
 
 
rhinitis, conjunctivitis, urticaria, asthma, anaphylaxis, 
bronchoconstriction and vascular permeability in the lung↑, 
immune response↑ 
 
2-methylhistamine, 2-(3-trifluoromethylphenyl)histamine, 
histaprodifen(s) 
 
1st generarion: chlorpromazine, chlorpheniramine, 
mepyramine, diphenhydramine, clemastine 
 
2nd generation: cetirizine, loratadine, astemizole, 
terfenadine, tripolidine 
 
 
H2R 
Gene locus 
 
Amino acids 
 
Expression pattern 
 
 
 
Signal transduction 
(main pathways) 
 
(Patho)physiological function 
 
 
 
Agonists 
 
 
Antagonists/inverse agonists 
 
 
 
 
5q35.2 
 
359 
 
gastric parietal, right atrial and ventricular muscle cells, 
airway and vascular smooth muscle cells, neurons, 
promyelocytic leukemic cells, hematopoietic cells 
 
Gαs → AC↑, [cAMP]↑; protein kinases↑; [Ca
2+]↑ 
 
 
gastric acid secretion↑, positive chronotropic and inotropic 
activity, cell differentiation↑ 
 
 
dimaprit, amthamine, impromidine, arpromidine 
 
 
cimetidine, raniditine, tiotidine, famotidine, aminopotentidine 
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H3R 
Gene locus 
 
Amino acids 
 
Expression pattern 
 
 
 
Signal transduction 
(main pathways) 
 
(Patho)physiological function 
 
 
 
Agonists 
 
 
Antagonists/inverse agonists 
 
 
 
 
 
 
 
 
20q13.33 
 
445 
 
histaminergic neurons, low concentrations in peripheral 
tissues 
 
 
Gαi/o → AC↓, [cAMP]↓; [Ca
2+]↓ 
 
 
presynaptic autoreceptor (controlling HA release and 
synthesis↓) and heteroreceptor (controlling release of other 
neurotransmitters↓) 
 
(R)-α-methylhistamine, imetit, immepip 
 
 
thioperamide, ciproxyfan, clobenpropit, JNJ-5207852 
 
H4R 
Gene locus 
 
Amino acids 
 
Expression pattern 
 
 
 
Signal transduction 
(main pathways) 
 
(Patho)physiological function 
 
 
 
Agonists 
 
 
Antagonists/inverse agonists 
 
 
 
 
18q11.2 
 
390 
 
hematopoietic and immunocompetent cells; low expression 
in brain, liver, and lung; neurons in the periphery  
 
 
Gαi/o → AC↓, [cAMP]↓; PLC↑; [Ca
2+]↑ 
 
 
chemotaxis in mast cells and eosinophiles↑; HA-induced 
itching↑ 
 
 
OUP-16, 4(5)-methylhistamine, UR-PI376 
 
 
JNJ-7777120, thioperamide 
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1.4.4 The histamine H3 receptor 
 
1.4.4.1 Molecular and biochemical pharmacology 
 
 In 1983, Arrang et al. pharmacologically identified the H3R as presynaptic 
autoreceptor inhibiting histamine release from histaminergic neurons in rat brain (Fig. 1.6). 
Histaminergic neurons are located exclusively in the tuberomammilary nucleus of the 
posterior hypothalamus, project to all major brain areas and are involved in fundamental 
brain functions such as sleep/wakefulness, energy homeostasis and cognition. Histaminergic 
neurotransmission was recently described in reviews by Panula and Haas (Haas and Panula, 
2003; Haas et al., 2008). Although H3Rs can also be found in the periphery, the great 
majority of H3Rs are expressed in the brain, e. g. in cerebral cortex, hippocampus, amygdala, 
nucleus accumbens, globus pallidus, striatum and hypothalamus. H3R expression is not 
restricted to histaminergic neurons. The H3R is also known to function as a heteroreceptor, 
modulating the release of other important neurotransmitters, like norepinephrine, 
acetylcholine, dopamine, serotonin and GABA. 
The H3R was cloned in 1999 by Lovenberg and co-workers, almost 20 years after its 
pharmacological characterization (Lovenberg et al., 1999). The reason for this delay was an 
unexpectedly low sequence homology to H1R and H2R. In a search for orphan GPCRs, a 
potential GPCR-related expressed sequence tag (EST) with homology to α2-adrenergic 
receptors was identified in silico and used to clone a full-length cDNA from a human 
thalamus library. The cDNA contained an open reading frame of 445 amino acids with all 
features characteristic of a family I GPCR for a biogenic amine. The overall sequence 
homology of the H3R to H1R and H2R is only 22% and 20%, respectively. 
 Due to the complex gene structure, a large number of H3R isoforms exists (Hancock 
et al., 2003). This is possible through alternative splicing of H3R mRNA. The H3R gene 
consists of three exons and two introns. So far, at least 20 isoforms of the human H3R have 
been identified on the basis of detection of varying mRNAs, but their regional expression and 
function remains largely unknown. The full-length H3R (445 amino acids) is currently the best 
characterized isoform. Of interest, most splice variants have deletions in the e3 loop, an 
important region involved in G protein coupling (Bongers et al., 2007). In recombinant 
systems, it was already shown that these isoforms have altered signalling properties 
compared to the full-length receptor. 
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Fig. 1.6: H3R auto- and heteroreceptor function in the nervous system. 
 
 In addition to H3R splice variants, there is some evidence for genetic polymorphism 
within the H3R gene. The amino acid at position 19 is reported to be either glutamic acid or 
aspartic acid (Lovenberg et al., 1999; Lovenberg et al., 2000a; Yao et al., 2003a). A second 
polymorphism, resulting from an alanine to valine substitution at amino acid 280 has been 
found in a patient with Shy-Drager syndrome (neurological orthostatic hypotension), a 
disease that is characterized by neuronal degeneration and autonomic failure (Wiedemann et 
al., 2002; Hancock et al., 2003). A third H3R polymorphism, resulting from a tyrosine to a 
cysteine substitution at position 197, has also been identified (Hancock et al., 2003). 
However, at present there is no information available on the potential functional differences 
between polymorphic H3R variants. 
 The H3R was also cloned from various other species, including monkey (Yao et al., 
2003b), guinea pig (Cassar, 2000; Tardivel-Lacombe et al., 2000), rat (Lovenberg et al., 
2000b; Drutel et al., 2001) and mouse (Rouleau et al., 2004). The cDNA of these H3R 
species homologs is very similar (>90%), but there are considerable pharmacological 
species differences. Most importantly, many antagonists have a higher affinity at rodent vs. 
human H3Rs (Ireland-Denny et al., 2001; Stark et al., 2001) (Fig. 1.7). In addition, H3R splice 
variants are not only limited to human H3Rs, but also exist in other species (Hancock et al., 
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2003). Moreover, the expression pattern of these isoforms also differs between species, 
adding another layer of complexity. The species-specificity of H3R splicing events renders 
data translation to humans very difficult. 
 
 
 
Fig. 1.7: Snake representation of the human H3R. 
 
 After the cloning of H3R, knock-out mice (H3R
-/-) were generated by independent 
laboratories (Takahashi et al., 2002; Toyota et al., 2002). Collectively, the derived results 
confirmed data from previous pharmacological studies with H3R ligands. However, the 
phenotype of H3R
-/- mice was different from wild type mice treated with H3R antagonists with 
respect to arousal and food intake. Since conditional H3R
-/- mice are not yet available, 
compensatory mechanisms have been put forward to explain the apparent anomalies. 
 H3Rs couple to Gαi/o-proteins (Fig. 1.8). This was originally shown by the pertussis 
toxin-sensitivity of H3R agonist-dependent [
35S]GTPγS binding in rat brain homogenate (Clark 
and Hill, 1996). 
 
Chapter 1: General Introduction 
 
16 
 
Fig. 1.8: H3R-mediated signal transduction – HA synthesis and release. H3R, histamine H3-
receptor; Gαi/o, inhibitory G protein α-subunits of the Gαi/o-family; β, G protein β-subunits; γ, G 
protein γ-subunits; AC, adenylate cyclase; PKA, protein kinase A; HDC, histidine 
decarboxylase; VACC, voltage-activated calcium channels; CaMKII, calmodulin kinase II. 
 
 
It has been confirmed by heterologous expression of the H3R in various mammalian cell 
lines, where H3R-activation results in AC-inhibition (Lovenberg et al., 1999). AC catalyzes the 
formation of the second messenger cyclic AMP (cAMP). It was also shown, that a reduction 
of cAMP-levels leads to an inhibition of HDC and thus, to a decrease in HA synthesis in pre-
synaptic histaminergic neurons (Gomez-Ramirez et al., 2002). However, an inhibition of HA 
release into the synaptic cleft is mainly triggered due to a decrease in intracellular Ca2+-
concentration (Moreno-Delgado et al., 2009). Here, an inhibition of voltage-gated ion 
channels plays a role. This differentiation was possible in studies with rat cortical miniprisms, 
leaving the natural environment of H3Rs intact. For this purpose, cortical lobes of rat brains 
were dissected and sliced into small miniprisms (0.3 mm/side) using a special tissue 
chopper. Other signal transduction pathways modulated by the H3R are for example 
activation of PLA2, MAPK and the PI3K-PKB-GSK3β axis (Leurs et al., 2005; Bongers et al., 
2007). An activation of MAPK and PI3K results in a phosphorylation of extracellular signal-
regulated kinases (ERKs) and protein kinase B (PKB or Akt), respectively. Active PKB 
phosphorylates and thereby inhibits glycogen synthase kinase 3β (GSK3β) activity, a major 
tau kinase in the brain. Activation of MAPK and PI3K are involved in memory consolidation, 
whereas the role of PKB/GSK3β, modulated by the H3R in the brain is less clear. However, 
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dysregulation of GSK3β is associated with diabetes and/or insulin resistance and 
Alzheimer´s disease. 
H3Rs are also constitutively active (Arrang et al., 2007). They can signal in the 
absence of an agonist, which was even shown in vivo. Using rat cortical miniprisms, it could 
be shown that HA-synthesis and -release are controlled by the constitutive activity of H3R, 
although to a different extent (Gomez-Ramirez et al., 2002; Moreno-Delgado et al., 2009). 
Due to the high constitutive activity of H3R, almost all H3R antagonists had to be re-classified 
as inverse agonists. 
Interestingly, there is also some evidence that H3Rs can exist as homo- or hetero-
dimers and/or –oligomers (Shenton et al., 2005). Functional interactions between the 
dopamine receptors (D1R and D2R) and H3R have already been described in the literature 
(Sanchez-Lemus and Arias-Montano, 2004; Humbert-Claude et al., 2007; Ferrada et al., 
2008). In recombinant systems, activation of MAPKs by H3Rs did not occur until D1Rs were 
co-expressed (Ferrada et al., 2009). Moreover, D1Rs, usually coupled to Gαs, coupled to Gαi/o 
in co-transfected cells. Additionally, signalling via each receptor was not only blocked by a 
selective antagonist, but also by an antagonist of the partner receptor. 
 
1.4.4.2 H3R ligands 
 
 As above mentioned, the H3R is an auto- and heteroreceptor. Thus, their activation 
reduces, whereas blockade increases, not only the release of HA but also several other 
neurotransmitters. Almost all H3R agonists are small molecule derivatives of HA (De Esch 
and Belzar, 2004) (Fig. 1.9). So far, efforts to replace the imidazole-moiety in agonists have 
been unsuccessful. Methylation of the basic amine group yields Nα-methylhistamine, a H3R 
agonist that is frequently used as radioligand in its tritiated form. Methylation of the imidazole 
side chain results in (R)-α-methylhistamine, which is the archetypal H3R agonist, used for the 
first pharmacological characterization of the H3R. Relatively small structural changes lead to 
very potent and selective H3R agonists like imetit or immepip. Methylation of the piperidine 
nitrogen of immepip gives methimepip, currently the most potent and selective H3R agonist. 
Impentamine, a higher homolog of histamine, proxyfan and GT-2331 (cipralisant) were 
originally characterized to be H3R antagonists. However, subsequent studies revealed the 
agonistic nature of the compounds. The first potent and selective H3R antagonist was 
thioperamide (Stark et al., 2004). This compound and many other imidazole-containing H3R 
antagonists, like ciproxyfan or clobenpropit, had to be re-classified as inverse agonists due to 
the constitutive activity of the H3R. Thioperamide was the reference H3R antagonist for 
almost two decades. Today, it is known that thioperamide, as well as many other imidazole-
containing H3R ligands, shows high antagonistic potency at the structurally related H4R, 5-
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HT3R, α2AAR and α2BAR. These off-target effects, the low bioavailability and blood-brain 
barrier penetration, and CYP450-inhibition due to the imidazole-moiety of many H3R ligands, 
lead to the development of more drug-like molecules as H3R antagonists/inverse agonists 
(Fig. 1.10). The replacement of the imidazole-moiety was crucial towards more selective and 
drug-like H3R antagonists. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.9: Imidazole-containing H3R-ligands. 
 
Nonetheless, there are still problems in the preclinical development of these ligands, e. g. 
inappropriate pharmacokinetics or toxic effects like phospholipidiosis. In recent years, a very 
large variety of non-imidazole H3R antagonists have been introduced and many of them are 
already in clinical trials. An interesting approach to fine tune the effects of H3R ligands is also 
a combination of H3R antagonism and selective inhibition of enzymes (Petroianu et al., 
2006), like acetylcholine esterase (Bembenek et al., 2008), or parallel transporter blockade, 
for example serotinin reuptake (Barbier et al., 2007). 
Chapter 1: General Introduction 
 
19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.10: Non-imidazole H3R-antagonists/inverse agonists. 
 
The preclinical development of non-imidazole H3R antagonists/inverse agonists 
(Bonaventure et al., 2007; Esbenshade et al., 2008; Stocking and Letavic, 2008) and first 
reports on clinical trials are subjects of some excellent reviews (Wijtmans et al., 2007; 
Sander et al., 2008; Gemkow et al., 2009). 
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1.5 The baculovirus/Sf9 cell system 
 
 There are numerous methods to study ligand binding, receptor activation and G 
protein/effector coupling. Each methodological approach has its specific applications, 
advantages and disadvantages, and provides distinct information. Optimally, several different 
approaches should be used to obtain as much information as possible on a given GPCR. 
With a baculovirus/Sf9 cell expression system, various basic steps in GPCR signal 
transduction can be investigated (Seifert and Wieland, 2005). 
 Sf9 insect cells, derived from Spodoptera frugiperda pupal ovarian tissue, are very 
suitable for protein expression, especially GPCRs (Aloia et al., 2009). As expression vectors, 
recombinant baculoviruses have to be generated (Preuss et al., 2007a; Schneider et al., 
2009). Baculoviruses are double-strained, filamentous DNA-viruses, which infect only non-
vertebrate hosts. Autographa californica nuclear polyhedrosis virus (AcNPV) is the best 
characterized baculovirus and routinely used for protein expression. AcNPV infects the clonal 
tissue culture line Sf9 and can be genetically modified. Wild-type AcNPV-DNA possesses a 
strong polyhedrin promoter, facilitating the production of polyhedrin, a matrix protein in which 
virus particles are embedded. The polyhedrin gene, 3´ to the promoter sequence, can be 
replaced by cDNA of interest, leading to a high expression level of the encoded protein. The 
BD BaculoGold™ linearized baculovirus DNA from BD Biosciences provides a tool for high 
recombination efficiencies. In principle, this modified type of baculovirus DNA contains a 
lethal deletion. The DNA does not code for viable virus. Only co-transfection of insect cells 
with the viral DNA and a complementing transfer vector construct reconstitutes viable virus. 
The foreign cDNA to be expressed has to be cloned into the transfer vector (Fig. 1.11). 
If the engineered baculovirus encodes for a GPCR or G protein, high expression 
levels can be achieved (Seifert et al., 1998; Ratnala et al., 2004; Schneider et al., 2009). 
Baculovirus expression provides correct folding of recombinant protein as well as disulfide 
bond formation and other important post-translational modifications. Most mammalian family 
I receptors and G proteins expressed in Sf9 cells are properly integrated into the 
membranous lipid bilayer and thus, reconstitution of receptor/G protein-coupling is feasible. 
Sf9 cells do not express any constitutively active GPCRs or relevant amounts of other 
receptors. Another advantage of Sf9 cells as GPCR expression system is the limited 
endogenous G-protein signalling, which leads to excellent signal to noise ratios 
(Quehenberger et al., 1992; Wenzel-Seifert et al., 1998; Brys et al., 2000; Seifert and 
Wenzel-Seifert, 2003). 
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Fig. 1.11: Generation of recombinant H3R-baculoviruses, protein expression and membrane 
preparation. 
 
 In this work, studies were only performed with broken-cell preparations (membranes) 
and not whole cells. Studies with membranes have many advantages, particularly when 
constitutive GPCR signalling is investigated. Contaminating agonists that may cause an 
apparent GPCR activation can be eliminated through multiple rounds of membrane 
centrifugation and resuspension. When working with whole cells or native brain tissue, an 
elimination of endogenous HA can be very difficult if not impossible. To ensure an absolute 
absence of endogenous HA one would have to study tissue derived from HDC-/- mice, keep 
the animals under sterile conditions and provide HA-free food. In the case of Sf9 cell 
membranes, also a precise control of the concentrations of GTP, ions and pH, all of which 
have an effect on constitutive GPCR activity, is possible (Seifert et al., 1999, 2001; Ghanouni 
et al., 2000; Seifert and Wenzel-Seifert, 2001). This might be artificial, but given the unknown 
composition of the precise chemical microenvironment of GPCRs and G proteins near the 
plasma membrane, the importance of data derived from these experiments cannot be 
dismissed. 
 Studies with membranes are also crucial for study of the impact of G proteins on 
signalling properties of GPCRs. Experiments with membranes allow analysis of GPCR 
activity not only at the level of ligand binding, but also directly at the G protein level (i. e., 
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GDP/GTP exchange and steady-state GTP hydrolysis). Moreover, using a baculovirus/Sf9 
cell expression system the G protein coupling profile of a given GPCR can easily be 
elucidated (Wenzel-Seifert et al., 1999, 2001; Brys et al., 2000; Wenzel-Seifert and Seifert, 
2000; Gazi et al., 2003). Again, studies with native tissue require the availability of several G 
protein knock-out mice (Albarran-Juarez et al., 2009). As an alternative, photoaffinity 
labelling using [α-32P]AA-GTP can be performed, if potent and selective GPCR ligands and 
selective antibodies are available (Klemke et al., 2000; Woo et al., 2009). Nevertheless, 
these methods are much more laborative than the reconstitution approach. 
 
 
1.6 Scope and Objectives 
 
The identification of the histamine H3-receptor (H3R) opened attractive perspectives 
for an exploitation of this new drug target. Since the initial cloning, a lot of knowledge about 
the molecular and biochemical pharmacology of this GPCR was accumulated. Numerous 
potent and selective H3R-ligands were identified and serve as pharmacological tools or 
potential therapeutics. There are, however, still some ligand effects that cannot be easily 
explained, based on the currently available data. 
The first aim of this thesis was to establish a sensitive, robust and uniform assay 
system to analyze all histamine receptors and their ligands under identical experimental 
conditions. So far, test systems to study these GPCRs are very heterogeneous and use 
many different pharmacological read-outs. Therefore, already existing baculovirus/Sf9 cell 
systems for the analysis of H1R, H2R and H4R (Kelley et al., 2001; Houston et al., 2002; 
Schneider et al., 2009) were complemented by a new system to study H3R. This system 
provides the basis for further molecular studies. 
As a second aim, the G protein coupling-profile of the H3R should be investigated. It is 
known, that H3R couples to pertussis toxin-sensitive G proteins of the Gi/Go-family, but 
detailed information about the interaction with specific G protein-subunits is not available. 
There are some ligands which show pleiotropic effects (Fox et al., 2002; Gbahou et al., 2003; 
Krueger et al., 2005; Ito et al., 2006). Therefore, the role of certain G protein α-subunits had 
to be investigated with respect to this matter. 
Additionally, a system to study rat H3R, a common laboratory animal to study H3R-
ligand effects, was generated. Deeper insights into the multiple functional species-
differences of all histamine receptors in general, and H3Rs in particular, will facilitate the 
development of more potent and selective ligands and increase our understanding of ligand-
receptor interactions (Preuss et al., 2007b, c; Strasser et al., 2008b, 2009; Deml et al., 2009; 
Igel et al., 2009; Kraus et al., 2009; Wittmann et al., 2009). Moreover, for the design of a 
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suitable pharmacological tool, it is absolutely necessary to know its functional properties on 
every relevant GPCR species homolog in an unbiased manner (Pertz et al., 2006; Xie et al., 
2006, 2007; Preuss et al., 2007a; Strasser et al., 2008a). The experimental studies should be 
complemented by molecular modelling approaches. 
Finally, it is generally poorly understood how the ionic environment changes the 
pharmacological properties of a GPCR (Costa et al., 1990; Seifert, 2001; Schneider et al., 
2009). Therefore, by using H3R as a model system, the influence of different monovalent ions 
on receptor-to-G protein coupling were investigated. In particular, a potential interaction-site 
for Na+-ions, highly conserved among GPCRs, was mutated and studied (Horstman et al., 
1990; Ceresa and Limbird, 1994). 
In summary, this thesis further characterizes the structure and function of H3R 
species homologs as well as the ligand-receptor interactions by an interdisciplinary approach 
comprising pharmacological assays, site-directed mutagenesis and molecular modelling. 
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2.1 Abstract 
 
Numerous structurally diverse ligands were developed to target the human histamine 
H3-receptor (hH3R), a presynaptic Gi/Go-coupled auto- and heteroreceptor. Proxyfan was 
identified to be functionally selective, with different efficacies towards Gi/Go-dependent hH3R 
signalling pathways. However, the underlying molecular mechanism of functional selectivity 
of proxyfan is still unclear. In the current study, we investigated the role of different Gαi/o 
proteins in hH3R signalling, using a baculovirus/Sf9 cell expression system. We tested the 
hypothesis that ligand-specific coupling differences to defined Gi/Go-heterotrimers are 
responsible for functional selectivity of proxyfan at hH3R. In Sf9 membranes, full-length hH3R 
(445 amino acids) was expressed in combination with an excess of different mammalian G 
proteins (Gαi1, Gαi2, Gαi3 or Gαo1, and β1γ2 dimers, respectively). Additionally, we constructed 
the fusion proteins hH3R-Gαi2 and hH3R-Gαo1 to ensure clearly defined receptor/G protein 
stoichiometries. Steady-state GTPase experiments were performed to directly measure the 
impact of each G protein on hH3R signal transduction. The hH3R coupled similarly to all G 
proteins. We also observed similar ligand-independent or constitutive activity. Proxyfan and 
various other imidazole-containing ligands, including full agonists, partial agonists and 
inverse agonists showed very similar pharmacological profiles, not influenced by the type of 
G protein co-expressed. Selected ligands, examined in membranes expressing the fusion 
proteins hH3R-Gαi2 and hH3R-Gαo1 (plus β1γ2 dimers), yielded very similar results. 
Collectively, our data indicate that hH3R couples similarly to different Gαi/o subunits and that 
ligand-specific active receptor conformations, resulting in G-protein coupling preferences, do 
not exist for proxyfan or other imidazole compounds investigated. 
 
 
2.2 Introduction 
 
The histamine H3-receptor (H3R) is currently one of the most targeted biogenic amine 
receptors because it participates in important physiological processes like the sleep-wake 
cycle, eating behavior and cognition (Leurs et al., 2005). Discovered pharmacologically in the 
early 1980s and cloned almost 20 years later (Lovenberg et al., 2000), the H3R was shown to 
be a presynaptic auto- and heteroreceptor, regulating the release of neurotransmitters 
including histamine, dopamine, norepinephrine, serotonin and acetylcholine via negative 
feedback mechanisms (Haas et al., 2008). Thus, the H3R is a promising drug target for many 
diseases including obesity, sleep disorders such as narcolepsy and cognitive problems 
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associated with Alzheimer’s disease, attention deficit-hyperactivity disorder and 
schizophrenia (Bonaventure et al., 2007; Esbenshade et al., 2008). 
According to the two-state model of receptor activation, G protein-coupled receptors 
(GPCRs) isomerize from an inactive (R) state to an active (R*) state (Kenakin, 2001; Seifert 
and Wenzel-Seifert, 2002). In the R* state, GPCRs activate G proteins. Agonist-independent 
R to R* isomerization is referred to as constitutive activity and results in an increase in basal 
G protein activity. Agonists stabilize the R* state and further increase, whereas inverse 
agonists stabilize the R state and decrease, basal G protein activity. The H3R is constitutively 
active (Leurs et al., 2005) and couples to Gi/Go-proteins in native tissues (Clark and Hill, 
1996). 
Many GPCRs are able to signal through various intracellular pathways. Depending on 
the specific G proteins to which the GPCR is coupled functional ligand selectivity has been 
frequently observed (Kenakin, 2001, 2007). In this case, the ligand preferentially activates 
specific signaling pathways mediated by a single GPCR in a manner that challenges the 
above introduced two-state model. Based on such findings, a multiple-state model, implying 
the existence of ligand-specific conformational states, has been developed (Kenakin, 2001, 
2007; Kobilka and Deupi, 2007). Interestingly, even stereoisomers of one and the same 
compound can show different functional selectivities, providing an additional opportunity to 
control receptor-mediated effects (Seifert and Dove, 2009). 
Protean agonism is considered a special case of functional selectivity. A protean 
agonist presumably stabilizes a receptor conformation with a lower efficacy towards the G 
protein than the agonist-free constitutively active or agonist-stabilized GPCR state. The 
ligand then acts as an inverse agonist. In a quiescent system with low constitutive activity, 
the protean ligand can act as an agonist (Gbahou et al., 2003; Kenakin, 2007). 
Numerous structurally diverse H3R ligands have been synthesized as potential drug 
candidates or as pharmacological tools. Almost all H3R agonists are imidazole-containing 
small molecules, derived from the endogenous agonist histamine (Leurs et al., 2005). H3R 
antagonists/inverse agonists can be differentiated into imidazole-containing antagonists and 
non-imidazole antagonists (Cowart et al., 2004; Leurs et al., 2005). Proxyfan is a 
prototypical, imidazole-containing H3R ligand that was initially characterized as an antagonist 
(Hüls et al., 1996) (Fig. 2.1). Subsequent studies revealed a more complex pharmacological 
profile and proxyfan was re-classified as a protean agonist (Gbahou et al., 2003). However, 
the systems examined were all very different, rendering data interpretation difficult. In brief, 
proxyfan was examined in different species and measuring various parameters. Additionally, 
the parameters were often quite distal and the G protein constructs used to transfect 
recombinant cell lines do not represent the physiological coupling partners or were chimeric 
to redirect the signaling cascade (Krueger et al., 2005). Collectively, due to the large 
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differences between the systems examined it is very difficult to precisely define the molecular 
mechanism for the pleiotropic effects of proxyfan. 
By studying nine imidazole-containing H3R ligands (Fig. 2.1), we wished to obtain 
more direct evidence for the existence of different ligand-specific H3R conformations. Most 
importantly, we aimed at probing the hypothesis that the type of Gi/Go-protein α-subunit to 
which H3R couples is responsible for the differential effects of proxyfan. Therefore, we 
established a baculovirus/Sf9 cell expression system for the full-length hH3R (445 aa), in 
which the receptor can be expressed either alone or co-expressed with different Gi/Go-
protein α-subunits (Gαi1, Gαi2, Gαi3 or Gαo1, and β1γ2 dimers, respectively). Sf9 cells have 
already been successfully used for reconstitution of several Gi/Go-coupled GPCRs (Wenzel-
Seifert et al., 1998; Kleemann et al., 2008). The hH3R-expressing membranes were then 
studied under identical experimental conditions, focusing on steady-state GTPase activity, a 
proximal parameter of GPCR/G-protein coupling. Moreover, we examined the fusion proteins 
hH3R-Gαi2 and hH3R-Gαo1. GPCR-Gα fusion proteins ensure close proximity and defined 1:1 
stoichiometry of the signalling partners (Seifert et al., 1999b), ruling out the possibility that 
differences in receptor-to-G protein ratio account for potential differences in pharmacological 
properties of ligands at hH3R. 
 
 
2.3 Materials and methods 
 
2.3.1 Materials 
The cDNA for the hH3R was kindly provided by Dr. T. Lovenberg (Johnson & Johnson 
Pharmaceutical R&D, San Diego, CA, USA). All restriction enzymes and T4 DNA ligase were 
from New England Biolabs (Frankfurt, Germany). M-MLV Reverse Transcriptase was from 
Invitrogen (Carlsbad, CA, USA). Cloned Pfu polymerase was obtained from Stratagene (La 
Jolla, CA, USA). The DNA primers for PCR were synthesized by MWG Biotech (Ebersberg, 
Germany). Baculoviruses for Gαi1, Gαi2 and Gαi3 were donated by Dr. A. G. Gilman 
(Department of Pharmacology, University of Southwestern Medical Center, Dallas, TX, USA). 
Baculovirus for rat Gαo1 was donated by Dr. J. C. Garrison (University of Virginia, 
Charlottesville, VA, USA). Recombinant baculovirus encoding the unmodified version of 
Gβ1γ2 subunits was a kind gift of Dr. P. Gierschik (Dept. of Pharmacology and Toxicology, 
University of Ulm, Germany). Anti-hH3R Ig was from Bio-Trend (Cologne, Germany). The 
anti-FLAG Ig (M1 monoclonal antibody) and anti-His6 Ig were from Sigma (St. Louis, MO, 
USA). The antibodies recognizing Gαi/o-subunits (Gαcommon; AS 266) and Gβ-subunits 
(Gβcommon; AS 398/9), as well as purified Gαi2- and Gαo2-protein, were kindly provided by Dr. 
B. Nürnberg (Institute of Pharmacology, University of Tübingen, Germany). The Gαi1/2- and 
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Gαo-selective antibodies were from Calbiochem (San Diego, CA, USA). Histamine, (R)-α-
methylhistamine, Nα-methylhistamine, imetit, clobenpropit and thioperamide were from Tocris 
(Avonmouth, Bristol, UK). Impentamine, imoproxyfan and ciproxyfan were kind gifts from Dr. 
S. Elz (Dept. of Pharmaceutical/Medicinal Chemistry I, University of Regensburg, Germany). 
Proxyfan was synthesized by Dr. P. Igel (Department of Pharmaceutical/Medicinal Chemistry 
II, University of Regensburg, Germany). Ligand structures are depicted in Fig. 2.1. Stock 
solutions (10 mM) of all H3R ligands described in this paper were prepared in distilled water 
and stored at -20°C. [3H]JNJ-7753707 (= [3H]RWJ-422475) (30 Ci/mmol) was kindly donated 
by Dr. P. Bonaventure (Johnson & Johnson Pharmaceutical R&D, San Diego, CA, USA). 
[3H]Dihydroalprenolol (85-90 Ci/mmol) and [35S]GTPγS (1100 Ci/mmol) were obtained from 
Perkin Elmer (Boston, MA, USA). [γ-32P]GTP was prepared using GDP and [32P]Pi (8500-
9120 Ci/mmol orthophosphoric acid) (Perkin Elmer Life and Analytical Sciences, Boston, 
MA, USA) according to a previously described enzymatic labelling procedure (Walseth and 
Johnson, 1979). Unlabeled nucleotides were from Roche (Indianapolis, IN, USA) and all 
other reagents were of the highest purity available and from standard suppliers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.1. Structures of imidazole-containing H3R ligands: full agonists 1-3, partial agonists 
4-6 and antagonists/inverse agonists 7-9. 
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2.3.2 Construction of FLAG epitope- and hexahistidine-tagged cDNA for hH3R 
The cDNA for the tagged receptor protein was generated by sequential overlap-
extension PCR. With pGEM-3Z-SF-hH4R-His6 as template (Schneider et al., 2009), PCR 1A 
was used to amplify a DNA fragment consisting of the cleavable signal peptide from 
influenza hemagglutinin (S), the FLAG epitope (F) recognized by the monoclonal antibody 
M1 and a start codon. The sense primer F1a (5´-GAC CAT GAT TAC GCC AAG C-3´) 
annealed with 19 bp of pGEM-3Z prior to the 5´-end of SF. The antisense primer C3 (5´-CAT 
GGC GTC ATC ATC GTC-3´) annealed with 15 bp of the 3´-end of SF and with ATG. In PCR 
1B, the cDNA encoding the hH3R, followed by a hexahistidine tag (His6) in 3´-position, was 
generated. The hexahistidine tag was included to allow future purification, to provide 
additional protection against proteolysis and to serve as a linker in fusion proteins between 
the hH3R and G-proteins (Seifert et al., 1998). The sense primer HUMAN HRH3-F- (5´-GAC 
GAT GAT GAC GCC ATG GAG CGC GCG CCG CC-3´) consisted of 15 bp of the 3’-end of 
SF and the first 17 bp of the 5’-end of the hH3R. The antisense primer HUMAN HRH3-RV 
(5´- GA TCC TCT AGA TTA GTG ATG GTG ATG ATG GTG CTT CCA GCA GTG CTC-3´) 
consisted of 15 bp of the C-terminus of the hH3R, the hexahistidine tag, the stop codon, and 
an Xba I site. As template, a plasmid (pCIneo) containing the sequence of hH3R was used. In 
PCR 2, the products of PCR 1A and PCR 1B annealed in the region encoding SF and ATG. 
Here, the sense primer of PCR 1a and the antisense primer of PCR 1b were used. In that 
way, a fragment encoding SF, the hH3R sequence, the hexahistidine tag, the stop codon, 
and an Xba I site was obtained. The fragment was digested with Sac I and Xba I and cloned 
into pGEM-3Z-SF-hH4R-His6, digested with the same restriction enzymes, to yield pGEM-3Z-
SF-hH3R-His6. After transformation of chemically competent bacteria (JM 109), amplification 
of the plasmids and analytical restriction digestion, the subcloned hH3R construct was fully 
sequenced. Finally, the construct was cloned into the baculovirus transfer vector pVL1392-
SF-hH4R-His6 (Schneider et al., 2009) via Sac I and Xba I restriction sites. Again, competent 
bacteria (Top 10) were transformed, the plasmid amplified and the accuracy of the resulting 
MaxiPrep-DNA checked by extensive restriction digestion analysis and sequencing. 
 
2.3.3 Construction of the cDNAs for hH3R-Gαi2 and hH3R-Gαo1 
The cDNAs for the tagged fusion proteins were also generated by sequential overlap-
extension PCR. With pGEM-3Z-SF-hH3R-His6 as template, a prolonged sense primer from 
PCR 1A F1b (5´- GAC CAT GAT TAC GCC AAG CTA TTT AGG TGA CAC TAT AGA ATA 
CTC AAG C-3´) and an antisense primer a6His_H3R (5´-GTG ATG GTG ATG ATG GTG 
CTT CCA GCA GTG C-3´), in PCR 3A a fragment encoding SF, the cDNA for the hH3R, and 
the hexahistidine tag was generated. In PCR 3B, a fragment encoding the hexahistidine tag, 
the cDNA for Gαi2 or Gαo1, the stop codon, and an Xba I site was generated. Here, the sense 
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primer annealed with the hexahistidine tag, the start codon and 5 N-terminal codons of Gαi2, 
s6HGia2 (5´- CAC CAT CAT CAC CAT CAC ATG GGC TGC ACC GTG AGC-3´), or Gαo1, 
s6HGaoA (5´- CAC CAT CAT CAC CAT CAC ATG GGA TGT ACG CTG AGC-3´). The 
antisense primer annealed with the cDNA encoding the 5 C-terminal amino acids of Gαi2 or 
Gαo1, the stop codon, and an Xba I site, aGia2XbaI (5´-GGT CGA CTC TAG AGG TCA GAA 
GAG GCC ACA GTC-3´) and aGaoAXbaI (5´-CGA CGG ATC CTC TAG AGG TCA GTA 
CAA GCC GCA GCC-3´). In PCR 4, the products of PCRs 3A and 3B annealed in the 
hexahistidine region, and the sense primer of PCR 1A and the antisense primers of PCR 3B 
were used. In that way, the complete cDNAs for the hH3R-Gαi2 and hH3R-Gαo1 fusion 
proteins, consisting of SF, the cDNA for the hH3R, the hexahistidine tag, and the cDNAs of 
Gαi2 or Gαo1 were amplified. These fragments were digested with Sac I and Xba I and cloned 
into pGEM-3Z-SF-hH4R-His6, digested with the same restriction enzymes, to yield pGEM-3Z-
SF-hH3R-Gαi2-His6 and pGEM-3Z-SF-hH3R-Gαo1-His6. After transformation of chemically 
competent bacteria (JM 109), amplification of the plasmids and analytical restriction 
digestion, the subcloned fusion constructs were fully sequenced. Finally, the constructs were 
cloned into the baculovirus transfer vector pVL1392-SF-hH4R-His6 via Sac I and Xba I 
restriction sites. Again, competent bacteria (Top 10) were transformed, the plasmids 
amplified and the accuracy of the resulting MaxiPrep-DNA checked by extensive restriction 
digestion analysis and sequencing. 
 
2.3.4 Generation of recombinant baculoviruses, cell culture and membrane 
preparation 
Baculoviruses encoding recombinant proteins were generated in Sf9 cells using the 
BaculoGOLD transfection kit (BD PharMingen, San Diego, CA, USA) according to the 
manufacturer’s instructions. Sf9 cells were cultured in 250- or 500-ml disposable Erlenmeyer 
flasks at 28 °C under rotation at 150 rpm in SF 900 II medium (Invitrogen, Carlsbad, CA, 
USA) supplemented with 5 % (v/v) fetal calf serum (Biochrom, Berlin, Germany) and 0.1 
mg/ml gentamicin (Cambrex Bio Science, Walkersville, MD, USA). Cells were maintained at 
a density of 0.5 – 6.0 x 106 cells/ml. After initial transfection, high-titer virus stocks were 
generated by two sequential virus amplifications. In the first amplification, cells were seeded 
at 2.0 x 106 cells/ml and infected with a 1:100 dilution of the supernatant from the initial 
transfection. Cells were cultured for 7 days, resulting in the death of virtually the entire cell 
population. The supernatant fluid of this infection was harvested and stored under light 
protection at 4 °C. In a second amplification, cells were seeded at 3.0 x 106 cells/ml and 
infected with a 1:20 dilution of the supernatant fluid from the first amplification. Cells were 
cultured for 48 h, and the supernatant fluid was harvested. After the 48 h culture period, the 
majority of cells showed signs of infections (e.g. altered morphology, viral inclusion bodies), 
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but most of the cells were still intact. The supernatant fluid from the second amplification was 
stored under light protection at 4 °C and used as routine virus stock for membrane 
preparations. To ensure the purity and identity of the viruses, the total RNA of infected Sf9 
cells was isolated (RNeasy Kit, Qiagen), the cDNA derived via reverse transcription, and 
fragments representative for the constructs PCR-amplified and analyzed by restriction 
digestion. For infection, cells were sedimented by centrifugation and suspended in fresh 
medium. Cells were seeded at 3.0 x 106 cells/ml and infected with a 1:100 dilution of high-
titer baculovirus stocks encoding hH3R constructs, Gαi/o-proteins and Gβ1γ2-dimers. Cells 
were cultured for 48 h before membrane preparation. Sf9 membranes were prepared as 
described previously, using 1 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 10 µg/ml 
benzamidine, and 10 µg/ml leupeptine as protease inhibitors. Membranes were suspended in 
binding buffer (12.5 mM MgCl2, 1 mM EDTA, and 75 mM Tris/HCl, pH 7.4) and stored at -80 
°C until use. 
 
2.3.5 SDS-PAGE and immunoblot analysis 
Membrane proteins were diluted in Laemmli-buffer and separated on SDS 
polyacrylamide gels containing 12 % (w/v) acrylamide. The purified G protein standards were 
handled in dilution buffer (Tris-HCl 25 mM, pH 7.5, DTT 1mM, NaCl 100 mM, Lubrol PX 0.1% 
(m/v), MgCl2 25 mM, EDTA 1 mM). Proteins were transferred onto 0.45 µm nitrocellulose 
membranes (Bio-Rad, Hercules, CA, USA) and then reacted with anti-hH3R (1:1000), M1 
antibody (1:1000), anti-His6 (1:5000), anti-Gαi1/2 (1:1000), anti-Gαo (1:1000), anti-Gαcommon 
(1:500) and anti-Gβcommon (1:1200) Ig´s. Immunoreactive bands were visualized by enhanced 
chemoluminescence (Pierce, Rockford, IL, USA), using anti-mouse and anti-rabbit Igs 
coupled to peroxidase (GE Healthcare, Little Chalfont, Buckinghamshire, UK). 
Electrochemoluminescence-stained blots were exposed to X-ray films (Amersham). The 
expression level of proteins were roughly estimated by using appropriate dilutions of a 
reference membrane expressing defined levels of hβ2AR protein or purified G proteins. 
hβ2AR expression levels were determined by radioligand binding with [
3H]dihydroalprenolol. 
Immunoblots were scanned with a GS-710 calibrated imaging densitometer (Bio-Rad). The 
intensity of the bands was analyzed with the Quantity One 4.0.3 software (Bio-Rad). 
 
2.3.6 [³H]JNJ-7753707 binding assay 
Before experiments, membranes were sedimented by a 10-min centrifugation at 4°C 
and 15,000g and resuspended in binding buffer (12.5 mM MgCl2, 1 mM EDTA, and 75 mM 
Tris-HCl, pH 7.4), to remove residual endogenous guanine nucleotides as much as possible. 
Each tube (total volume, 250 or 500 µl) contained 10 to 50 µg of protein. Non-specific binding 
was determined in the presence of [3H]JNJ-7753707 at various concentrations plus 10 µM 
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THIO and amounted to ~20 - 30% of total binding at saturating concentrations (10 nM). 
Incubations were conducted for 60 min at RT and shaking at 250 rpm. Saturation binding 
experiments were carried out using 0.3 to 10 nM [3H]JNJ-7753707. Bound [3H]JNJ-7753707 
was separated from free [3H]JNJ-7753707 by filtration through 0.3% (m/v) polyethyleneimine-
pretreated GF/C filters, followed by three washes with 2 ml of binding buffer (4°C). Filter-
bound radioactivity was determined by liquid scintillation counting. The experimental 
conditions chosen ensured that not more than 10 % of the total amount of radioactivity added 
to binding tubes was bound to filters. 
 
2.3.7 [35S]GTPγS binding assay 
Membranes were thawed and sedimented by a 10-min centrifugation at 4°C and 
15,000g to remove residual endogenous guanine nucleotides as far as possible. Membranes 
were resuspended in binding buffer, supplemented with 0.05% (m/v) BSA. Each tube (total 
volume of 250 or 500 µl) contained 10 - 20 µg of membrane protein. In saturation binding 
experiments, tubes contained 0.2 – 2 nM [35S]GTPγS plus unlabeled GTPγS to give the 
desired final ligand concentrations (0.2 – 50 nM). Neither GDP nor H3R ligands were 
included in assays. Non-specific binding was determined in the presence of 100 µM 
unlabeled GTPγS and amounted to less than 1% of total binding. Incubations were 
conducted for 90 minutes at 25°C and shaking at 250 rpm. Bound [35S]GTPγS was separated 
from free [35S]GTPγS by filtration through GF/C filters, followed by three washes with 2 ml of 
binding buffer (4°C). Filter-bound radioactivity was determined by liquid scintillation counting. 
The experimental conditions chosen ensured that not more than 10 % of the total amount of 
radioactivity added to binding tubes was bound to filters. 
 
2.3.8 Steady-state GTPase activity assay 
Membranes were thawed, sedimented and resuspended in 10 mM Tris/HCl, pH 7.4. 
Assay tubes contained Sf9 membranes (10 – 20 µg of protein/tube), 5.0 mM MgCl2, 0.1 mM 
EDTA, 0.1 mM ATP, 100 nM GTP, 0.1 mM adenylyl imidodiphosphate, 1.2 mM creatine 
phosphate, 1 µg of creatine kinase, and 0.2% (w/v) bovine serum albumin in 50 mM Tris/HCl, 
pH 7.4, and H3R ligands at various concentrations. Reaction mixtures (80 µl) were incubated 
for 2 min at 25°C before the addition of 20 µl of [γ-32P]GTP (0.1 µCi/tube). All stock and work 
dilutions of [γ-32P]GTP were prepared in 20 mM Tris/HCl, pH 7.4. Reactions were conducted 
for 20 min at 25°C. Reactions were terminated by the addition of 900 µl of slurry consisting of 
5% (w/v) activated charcoal and 50 mM NaH2PO4, pH 2.0. Charcoal absorbs nucleotides but 
not Pi. Charcoal-quenched reaction mixtures were centrifuged for 7 min at room temperature 
at 15,000g. Six hundred microliters of the supernatant fluid of reaction mixtures were 
removed, and 32Pi was determined by liquid scintillation counting. Enzyme activities were 
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corrected for spontaneous degradation of [γ-32P]GTP. Spontaneous [γ-32P]GTP degradation 
was determined in tubes containing all of the above described components plus a very high 
concentration of unlabeled GTP (1 mM) that, by competition with [γ-32P]GTP, prevents [γ-
32P]GTP hydrolysis by enzymatic activities present in Sf9 membranes. Spontaneous [γ-
32P]GTP degradation was <1% of the total amount of radioactivity added using 20 mM 
Tris/HCl, pH 7.4, as solvent for [γ-32P]GTP. The experimental conditions chosen ensured that 
not more than 10% of the total amount of [γ-32P]GTP added was converted to 32Pi. 
 
2.3.9 Miscellaneous 
Molecular biology was planned with GCK 2.5 (Textco BioSoftware, West Lebanon, 
NH, USA). Ligand structures were illustrated using ChemDraw Ultra 8.0 (CambridgeSoft, 
Cambridge, MA, USA). Protein was determined using the DC protein assay kit (Bio-Rad, 
Hercules, CA, USA). [3H]Dihydroalprenolol saturation binding was performed as described 
previously (Seifert et al., 1998). All analyses of experimental data were performed with the 
Prism 5 program (GraphPad Software, San Diego, CA, USA). When expression levels of 
recombinant proteins were determined by western blot, the Bio-Rad GS-710 Calibrated 
Imaging Densitometer and the software tool Quantity One version 4.0.3 (Bio-Rad, Hercules, 
CA, USA) was used. 
 
 
2.4 Results 
 
2.4.1 Immunological detection of recombinant proteins expressed in Sf9 cell 
membranes 
Membranes from the same batch of Sf9 cells infected with recombinant N- and C-
terminally tagged hH3R-baculoviruses alone or in combination with baculoviruses encoding 
different mammalian G proteins (Gα i1, Gα i2, Gα i3 or Gα o1 and/or β1γ2 dimers, respectively) 
were prepared and subjected to immunological analysis. The predicted molecular mass of 
the hH3R is ~49 kDa. We used anti-hH3R Ig, recognizing an 18 aa peptide within the 
extracellular N-terminus of the hH3R to confirm expression (Fig. 2.2A). Indeed, hH3R 
migrated as the expected band for a monomeric GPCR. The results were confirmed by the 
use of anti-FLAG Ig (Fig. 2.2B), recognizing the N-terminal FLAG-epitope and anti-His6 Ig 
(Fig. 2.2C), recognizing the C-terminal hexahistidine-tag. The bands were doublets, probably 
representing differently glycosylated forms of hH3R. hH3R possesses one putative N-
glycosylation site (Asn11), located in the N-terminus. The receptor expression levels were 
similar in all membrane batches and estimated to be ~1-2 pmol/mg, using anti-FLAG Ig and 
hβ2AR as standard (Fig. 2.2B). The expression level of the hβ2AR was 7.5 pmol/mg, as 
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determined by [3H]dihydroalprenolol saturation binding. Thus, hH3R was properly expressed 
in Sf9 cells and not proteolytically degraded after membrane preparation. 
In order to visualize the co-expressed Gα-subunits, we used an antibody recognizing 
all Gαi/o-proteins (Fig. 2.2D). Gαi/o-subunits appeared at the expected molecular mass (~40 – 
41 kDa) as very intense bands, although the expression level of Gαi1 was lower compared to 
the other ones. This is an intrinsic property of mammalian Gαi1 heterologously expressed in 
Sf9 cells, as already shown in a previous study (Kleemann et al., 2008). Unfortunately, this 
problem could not be overcome by an optimization of the expression process. However, it 
was also shown that a low expression level of Gαi1 does not influence its ability to effectively 
interact with GPCRs (Kleemann et al., 2008). Probably, Gαi1 accumulates in GPCR-
expressing membrane domains. Gβ1-subunits were expressed at similar levels in all 
membranes studied (Fig. 2.2E). 
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Fig. 2.2. Immunological detection of recombinant proteins expressed in Sf9 cells. Each 
lane of the gels was loaded with 10 µg of membrane protein, unless otherwise indicated 
below the film. Numbers on the left designate masses of marker proteins in kDa. In A, a 
membrane expressing the hH3R alone was loaded onto the gels. In B1 and B2, 2, 4, 6, 8 and 
10 µg of protein of Sf9 membranes expressing hβ2AR at 7.5 pmol/mg (as determined by 
[³H]dihydroalprenolol saturation binding) were used as standard to assess the expression 
levels of the hH3R in different membrane preparations with anti-FLAG Ig. In C, the same 
membranes were reacted with anti-His6 Ig. In D, the membranes were reacted with anti-Gαi-
common Ig. In E, the membranes were reacted with anti-Gβ-common Ig. In F, 0.5, 1.0, 1.5 and 2.0 
µg of a membrane expressing the hH3R + Gαi2 + β1γ2 was analyzed in order to quantify the 
Gα-subunits, using 2, 4, 7.5, 15 and 30 pmol of purified Gαi2 as standard. In G, 0.5, 1.0, 1.5 
and 2.0 µg of a corresponding membrane of the same batch expressing hH3R + Gαo1 + β1γ2 
was analyzed to quantify the Gα-subunits, using 2, 4, 7.5, 15 and 30 pmol of purified Gαo2 an 
almost identical splice variant of Gαo1 as standard. 
 
 
The GPCR/G protein ratio can alter the pharmacological properties of ligands 
(Kenakin, 1997). Therefore, we quantified Gαi2 and Gαo1 using purified protein as reference. 
These semi-quantitatively determined expression levels for the Gα-subunits were in the 
range of 50-100 pmol/mg, resulting in receptor-to-G protein ratios of ~1:50 – 1:100 (Figs. 
2.2F and 2.2G). This is in good agreement with ratios determined for other Gi/o-coupled 
receptors in Sf9 cell membranes, for example the hH4R (Schneider et al., 2009), human 
cannabinoid receptors CB1 and CB2 (Nickl et al., 2008) and the human formyl peptide 
receptor (Wenzel-Seifert et al., 1998). 
 
2.4.2 [³H]JNJ-7753707 and [35S]GTPγS binding. Quantitative analysis of receptor-to-G 
protein stoichiometry 
Due to the fact that the determination of expression levels by immunoblotting does 
not discriminate between functional and non-functional proteins, we also quantified the hH3R 
and Gα proteins by a combination of antagonist [³H]JNJ-7753707- and [35S]GTPγS-saturation 
binding and calculated the functional GPCR/Gα protein ratios (Table 2.1). The membranes 
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were from the same batch as those studied by immunoblot to ensure maximal comparability 
and data accuracy. 
 
Table 2.1: Quantification of hH3R-to-G protein ratios via [³H]JNJ-7753707- and 
[35S]GTPγS-saturation binding. 
 
 Bmax ± S. E. M. (pmol × mg
-1) 
hH3R + β1γ2 
membrane 
+ Gαi1 + Gαi2 + Gαi3 + Gαo1 
[³H]JNJ-7753707 0.6 ± 0.04 1.02 ± 0.07 1.2 ± 0.06 0.7 ± 0.03 
[35S]GTPγS 1.40 ± 0.57 5.78 ± 0.67 4.02 ± 0.80 7.83 ± 0.77 
R : G ratio  ~1 : 2 ~1 : 6 ~1 : 3 ~1 : 11 
 
 
[³H]JNJ-7753707 saturation bindings were performed as described under Materials and 
Methods. [35S]GTPγS saturation bindings were performed, using Sf9 cell membranes from 
the same batch of preparation. Reaction mixtures contained membranes (10 - 20 µg of 
protein), 0.2 - 2 nM of [35S]GTPγS, and unlabeled GTPγS to give the desired final ligand 
concentrations for saturation (0.2 – 50 nM). GDP or additional H3R ligands were not present 
in the reaction mixtures. Data were analyzed by nonlinear regression and were best fitted to 
hyperbolic one-site saturation isotherms. The maximal number of GTPγS binding sites in 
membranes expressing hH3R plus Gαi2 plus β1γ2 was corrected by the binding determined in 
hH3R plus β1γ2. By this way, the number of functionally intact and heterologously expressed 
G protein α-subunits was quantified. Data shown are the means ± S. E. M. of 3 independent 
experiments performed in triplicate. Receptor-to-G protein ratios were calculated, using the 
Bmax values determined for the different membrane preparations. 
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In [35S]GTPγS-saturation binding experiments neither GDP nor H3R ligands were 
present. The maximum number of Gαi/o-related GTPγS binding sites in membranes 
expressing hH3R plus Gα-subunits plus β1γ2 was corrected by the binding determined in 
parallel in membranes expressing hH3R plus β1γ2 alone. To ensure the same viral load in the 
reference membrane, Sf9 cells were infected with baculoviruses encoding hH3R, β1γ2 and 
virus encoding no recombinant protein at all. In this manner, only the number of functionally 
intact and heterologously expressed mammalian Gαi/o-subunits was quantified. 
The experiments revealed that the number of [³H]JNJ-7753707 binding sites was very 
similar to the hH3R protein expression levels determined via immunoblot. Thus, most hH3R 
molecules were correctly folded in Sf9 cell membranes. However, the number of specific 
[35S]GTPγS binding sites for mammalian Gα-proteins was much smaller when compared with 
the Gα-protein expression levels determined via immunoblot. Nevertheless, there were still 
more functionally intact mammalian G proteins than receptors in the membranes and the 
functional receptor-to-G protein ratios ranged between 1 : 2 and 1 : 11. Similar ratios were 
also found by other investigators, using the same methodology (Gazi et al., 2003). These 
data also fit to the linear and non-catalytic signal transfer observed for several GPCR/G-
protein pairs in Sf9 cell membranes (Wenzel-Seifert et al., 1998, 1999; Wenzel-Seifert and 
Seifert, 2000). 
 
2.4.3 Steady-state GTPase assay. hH3R coupling to different Gα-subunits 
To investigate the G protein coupling profile of the hH3R, we measured the receptor-
dependent [γ-32P]GTP hydrolysis of different Gα-subunits. The experiments were performed 
under steady-state conditions. Thus, multiple G protein activation/deactivation cycles were 
assessed, eliminating the inherent bias of kinetic [35S]GTPγS binding studies. GTP hydrolysis 
was determined in parallel under basal conditions, maximal stimulation with the physiological 
(and full) agonist histamine (10 µM) and a saturating concentration of the inverse agonist 
thioperamide (10 µM) in Sf9 cell membranes expressing the hH3R alone or co-expressing the 
hH3R and different G proteins. 
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Table 2.2: GTPase activities in Sf9 membranes expressing hH3R and different Gαi/o-
proteins. 
 
hH3R + β1γ2 
GTPase activity 
± S. E. M. 
- + Gαi1 + Gαi2 + Gαi3 + Gαo1 
basal 
(pmol × mg-1 × min-1) 
1.21 ± 0.04 1.98 ± 0.05 2.92 ± 0.13 2.08 ± 0.16 4.43 ± 0.40 
+ ago. 
(pmol × mg-1 × min-1) 
1.36 ± 0.03 2.56 ± 0.03 4.24 ± 0.22 3.10 ± 0.30 5.65 ± 0.47 
∆ ago. 
(pmol × mg-1 × min-1) 
0.15 ± 0.03 0.57 ± 0.07 1.31 ± 0.12 1.02 ± 0.20 1.21 ± 0.09 
Agonist stimulation 
(% of basal) 
12.63 ± 
3.10 
29.01 ± 
3.98 
44.82 ± 
3.51 
49.28 ± 
9.01 
27.50 ± 
1.40 
+ inv. ago. 
(pmol × mg-1 × min-1) 
1.07 ± 0.02 1.45 ± 0.17 1.64 ± 0.15 1.40 ± 0.22 3.34 ± 0.38 
∆ inv. ago. 
(pmol × mg-1 × min-1) 
0.14 ± 0.05 0.53 ± 0.13 1.29 ± 0.17 0.68 ± 0.10 1.09 ± 0.10 
Inverse agonist 
inhibition 
(% of basal) 
11.70 ± 
4.25 
27.20 ± 
6.85 
44.13 ± 
3.57 
33.45 ± 
5.83 
24.88 ± 
2.59 
 
Steady-state GTPase experiments were performed as described in Materials and Methods. 
Reaction mixtures contained 0.1 µCi [γ-32P]GTP and 100 nM unlabeled GTP in the presence 
of solvent (basal), 10 µM HA (+ ago.) or 10 µM THIO (+ inv. ago.). Data shown are the 
means ± S. E. M. of three to four independent experiments for each membrane preparation 
performed in duplicates. The absolute agonist-stimulation (∆ ago.) and inverse agonist-
inhibition (∆ inv. ago.) of GTP hydrolysis, as well as the relative agonist-stimulation and 
inverse agonist-inhibition of GTP hydrolysis (% of basal), were calculated. 
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In membranes expressing the hH3R alone, basal GTPase activity was low, and the 
stimulatory and inhibitory effects of histamine and thioperamide, respectively, were small 
(Table 2.2). This reflects only very weak coupling of the hH3R to insect cell G proteins. The 
structurally related hH4R also couples only weakly to insect cell G proteins (Schneider et al., 
2009). hH3R coupled efficiently to all co-expressed mammalian Gαi/o-subunits (Gαi1, Gαi2, Gαi3 
or Gαo1, and β1γ2 dimers, respectively) as was evident by the higher basal GTPase activity 
and the larger absolute stimulatory and inhibitory effects of histamine and thioperamide, 
respectively. The relative stimulatory effects of histamine and the relative inhibitory effects of 
thioperamide based on total ligand-regulated GTPase activity were similar for each of the five 
systems studied, indicating that the constitutive activity of hH3R was comparable and not 
substantially influenced by the type of G protein (Seifert and Wenzel-Seifert, 2002). In 
contrast to hH3R, the short and long splice variants of Gαs had a large impact on the 
constitutive activity of the hβ2AR (Seifert et al., 1998; Seifert, 2001). The constitutive activity 
of hH3R coupled to cognate Gi/Go-proteins was rather high and comparable to the 
constitutive activity of hH4R (Schneider et al., 2009) and the human formyl peptide receptor 
(Wenzel-Seifert et al., 1998, 1999). However, some Gi/Go-coupled GPCRs expressed in Sf9 
cells exhibit only low or no constitutive activity, indicating that the expression system per se 
does not give rise to high constitutive activity (Seifert and Wenzel-Seifert, 2002; Kleemann et 
al., 2008). 
 
2.4.4 Ligand potencies and efficacies in the steady-state GTPase assay at hH3R co-
expressed with different Gα-subunits 
Next, we examined a variety of imidazole-based ligands, including the functionally 
selective proxyfan, in Sf9 cell membranes expressing the hH3R and different Gαi/o-proteins in 
the steady-state GTPase assay (Fig. 2.1, Table 2.3). 
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The endogenous agonist histamine (1) and the standard H3R ligands N
α-
methylhistamine (2) and (R)-α-methylhistamine (3) were full agonists and equally potent in all 
membranes. The highly potent standard H3R agonist imetit (4) was almost a full partial 
agonist in this assay. Most interestingly, the protean agonist proxyfan (5) was a strong partial 
agonist in all systems, independent of the G protein subtype co-expressed (Fig. 2.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.3. Comparison of the effects of histamine, proxyfan and thioperamide in 
membranes expressing the hH3R, different Gαi/o subunits and β1γ2 dimers. Steady-state 
GTPase activity in Sf9 membranes was determined as described under Materials and 
Methods. Reaction mixtures contained histamine (HA), proxyfan (PRO) or thioperamide 
(THIO) at the concentrations indicated on the abscissa to achieve saturation. Data were 
analyzed by nonlinear regression and were best fit to sigmoidal concentration/response 
curves. Data points shown are the means ± S. E. M. of 3 - 4 independent experiments 
performed in duplicate. A summary of all results is shown in Table 2.3. 
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Impentamine (6) was a moderate partial agonist in all experimental settings. The 
inverse agonists ciproxyfan (7), clobenpropit (8) and thioperamide (9) each were also equally 
potent in the various systems, although they significantly differed in efficacy with the various 
Gαi/o-proteins. However, the rank orders of potency and efficacy of compounds 7 - 9 did not 
change under the various conditions. Thus, the pharmacological profile of the hH3R is very 
similar under the various experimental conditions. Additionally, there is a strong linear 
correlation between potencies and efficacies of H3R ligands at membranes expressing 
different Gαi/o-subunits (Fig. 2.4). An increase in constitutive activity of hH3R coupled to one 
G protein relative to another G-protein would have been reflected in increased agonist 
potency and efficacy (Seifert and Wenzel-Seifert, 2002), but such an observation was not 
made. Moreover, differences in constitutive activity of hH3R under the various conditions 
would have resulted in systematic changes of inverse agonist potency, i.e. an increase in 
constitutive activity would have resulted in decreased inverse agonist potency (Seifert and 
Wenzel-Seifert, 2002). Again, no such data were obtained. Collectively, these results 
corroborate the findings regarding the relative stimulatory and inhibitory effects of histamine 
and thioperamide, respectively (Table 2.2) based on total ligand-regulated GTPase activity 
and are indicative for similar constitutive activity of hH3R under all experimental conditions 
(Seifert and Wenzel-Seifert, 2002). 
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Fig. 2.4. Correlation of potency and efficacy of ligands at the hH3R in the presence of 
different co-expressed Gαi/o-proteins. Data shown in Table 2.3 were analyzed by linear 
regression. In A, C and E, the potencies of ligands at membranes co-expressing the hH3R, 
Gαi1, Gαi3 or Gαo1, and β1γ2 dimers, respectively, were correlated with values determined at 
the reference membrane expressing Gαi2. A, r
2 = 0.97; slope = 0.93 ± 0.06. C, r2 = 0.93; 
slope = 1.02 ± 0.10. E, r2 = 0.92; slope = 0.96 ± 0.11. In B, D and F, the efficacies of ligands 
at membranes co-expressing the hH3R, Gαi1, Gαi3 or Gαo1, and β1γ2 dimers, respectively, 
were correlated with values determined at the reference membrane expressing Gαi2. B, r
2 = 
0.99; slope = 0.87 ± 0.03. D, r2 = 0.99; slope = 0.78 ± 0.03. F, r2 = 0.99; slope = 0.85 ± 0.03. 
The dotted lines indicate the 95% confidence intervals of the regression lines. The diagonal 
dashed line has a slope of 1 and represents a theoretical curve for identical values. 
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2.4.5 Studies with hH3R-Gαi2 and hH3R-Gαo1 fusion proteins 
The use of co-expression systems is often hampered by the fact that it is difficult, if 
not impossible, to control the expression levels of different signalling partners exactly (Fig. 
2.2, Table 2.1) (Gille and Seifert, 2003; Kleemann et al., 2008). Table 2.1 shows that also for 
hH3R, identical GPCR/Gα ratios could not be achieved. The efficiency of interactions 
between GPCRs and heterotrimeric G proteins can be influenced by the absolute and 
relative densities of these proteins in the plasma membrane (Kenakin, 1997; Gille and 
Seifert, 2003). Fortunately, the analysis of these interactions is greatly facilitated by the use 
of GPCR-Gα fusion proteins (Seifert et al., 1999b). Fusion proteins ensure a defined 1:1 
stoichiometry of GPCR to Gα and ensure physical proximity of the signalling partners. 
Nonetheless, fusion proteins are not physiologically occurring and therefore, the 
academically best procedure is to compare co-expression systems directly with fusion 
proteins (Wenzel-Seifert et al., 1998, 1999; Wenzel-Seifert and Seifert, 2000). 
Pertussis toxin-sensitive G proteins consist of different Gαi/o-family members and βγ-
complexes (Birnbaumer, 2007). The three Gαi-subunits are all very similar in structure, 
whereas the two Gαo-splice variants are less conserved. The largest structural differences in 
this G protein family exist between Gαi2 and Gαo1 (Birnbaumer, 2007). Thus, we constructed 
hH3R-Gαi2 and hH3R-Gαo1 fusion proteins as representative pair to study hH3R/G protein 
coupling in more detail. We hypothesized that, if there were any hH3R/G protein coupling 
differences, then potencies and efficacies of ligands should diverge most prominently at this 
fusion protein pair. The assessment of GTPase activity at different GPCR-GαX fusion 
proteins is the most accurate measure of the pharmacological profile of a given receptor 
because GTPase activities are determined under steady-state conditions, rendering potency 
and efficacy values of agonists and inverse agonists expression level-independent (Seifert et 
al., 1999a,b; Wenzel-Seifert et al., 1999; Wenzel-Seifert and Seifert, 2000). The 
pharmacological profiles of histamine, imetit, proxyfan, clobenpropit and thioperamide in the 
GTPase assay were very similar at the hH3R-Gαi2 and hH3R-Gαo1 fusion proteins both in 
terms of potency and efficacy (Table 2.4). 
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Table 2.4: Potencies and efficacies of selected ligands in the GTPase assay at fusion 
proteins. 
 
 hH3R-Gαi2 + β1γ2 hH3R-Gαo1 + β1γ2 
 
pEC50 
± S. E. M. 
Emax ± S. E. M. 
pEC50 
± S. E. M. 
Emax ± S. E. M. 
HA 7.40 ± 0.10 1.00 7.46 ± 0.11 1.00 
IME 9.55 ± 0.19 0.96 ± 0.08 9.62 ± 0.09 0.95 ± 0.04 
PRO 7.65 ± 0.23 0.81 ± 0.08 7.76 ± 0.13 0.74 ± 0.05 
CLOB 8.72 ± 0.25 -0.60 ± 0.07 8.45 ± 0.25 -0.86 ± 0.09 
THIO 7.00 ± 0.18 -0.76 ± 0.07 7.05 ± 0.15 -0.74 ± 0.05 
 
 
Steady-state GTPase activity in Sf9 membranes expressing hH3R-Gαi2 or hH3R-Gαo1 plus 
β1γ2 was determined as described under Materials and Methods. Reaction mixtures 
contained ligands at concentrations from 0.1 nM to 10 µM as appropriate to generate 
saturated concentration/response curves. Data were analyzed by nonlinear regression and 
were best fit to sigmoid concentration/response curves. Typical basal GTPase activities 
ranged between 1.0 and 1.5 pmol × mg-1 × min-1, and the maximal stimulatory effect of HA 
(10 µM) amounted to ~50 to ~80% above basal. The efficacy (Emax) of HA was determined by 
nonlinear regression and was set to 1.00. The Emax values of other agonists and inverse 
agonists were referred to this value. Data shown are the means ± S. E. M. of three to four 
experiments performed in duplicates each. Statistical analysis was performed using the t-test 
(p < 0.05). Significant differences were not found for the data analyzed. 
 
Moreover, there was no evidence for differences in constitutive activity of the two 
fusion proteins. These results fit very well to the data obtained with the corresponding co-
expression systems (Table 2.3) and render it unlikely that the non-identical GPCR/Gα 
stoichiometries in the co-expression studies documented in Table 2.1 had a major impact on 
the pharmacological profile of hH3R. Actually, the stoichiometry issue would have been of 
greater concern if the pharmacological profiles of the hH3R had been different with the 
various co-expressed Gαi/o proteins. This was, however, not the case (Table 2.3). 
 
 
2.5 Discussion 
 
The imidazole-containing H3R ligand proxyfan exhibits pleiotropic effects, ranging 
from inverse agonism to agonism, depending on the system studied (Gbahou et al., 2003; 
Krueger et al., 2005). An explanation for these findings could be that the proxyfan-bound H3R 
exhibits different affinities and efficacies for coupling to various G-proteins (Kenakin, 2001, 
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2007; Kobilka and Deupi, 2007). Thus, the observed proxyfan effects could be due to 
functional selectivity. We tested this hypothesis by studying coupling of the hH3R to four 
different Gαi/o-proteins under clearly defined experimental conditions, measuring one and the 
same parameter of GPCR/G-protein coupling, i.e. steady-state GTPase activity. However, 
we did not obtain evidence for functional selectivity of proxyfan. In our hands, proxyfan was a 
strong partial agonist at the full-length hH3R (445 aa) in all experimental settings. For eight 
other hH3R ligands, we did not obtain evidence for functional selectivity either. Moreover, we 
could not find differences in constitutive activity of hH3R coupled to Gi/Go-proteins which 
would have been important for detecting protean agonism (Gbahou et al., 2003). Those 
“negative” data were obtained in a co-expression system and a fusion protein system. Thus, 
the crucial question is of how the discrepancies between our present study and the studies of 
Gbahou et al. (2003) and Krueger et al. (2005) could be explained. 
Defined ligands stabilize distinct conformations in the human dopamine D2-receptor 
that result in the activation of only one specific Gαi/o-subunit when expressed in Sf9 cells 
(Gazi et al., 2003). Additionally, endogenous catecholamines and synthetic ligands stabilize 
distinct ligand-specific active states in human β-adrenergic receptors (Seifert et al., 1999a; 
Wenzel-Seifert and Seifert, 2000; Weitl and Seifert, 2008). Moreover, ligand-specific 
conformations were readily unmasked for histamine H1- and H2-receptors expressed in Sf9 
cells (Preuss et al., 2007; Wittmann et al., 2009). These data show that the baculovirus/Sf9 
cell system is sufficiently sensitive at detecting ligand-specific GPCR conformations so that 
we should have been able to detect functional selectivity of proxfan. However, it should also 
be emphasized that for some GPCRs expressed in Sf9 cells, e.g. the human formyl peptide 
receptor, no evidence for ligand-specific receptor conformations could be obtained despite 
intense efforts (Wenzel-Seifert et al., 1999). These data indicate that not all GPCRs exhibit 
ligand-specific conformations. Noteworthy, like hH3R, the formyl peptide receptor couples to 
Gi/Go-proteins (Wenzel-Seifert et al., 1999). 
In the study of Gbahou et al. (2003), proxyfan was a partial agonist in [35S]GTPγS 
binding, cAMP accumulation and mitogen-activated protein kinase assays, but an inverse 
agonist in phospholipase A2 assays, all parameters representing distal consequences of 
Gαi/o-protein activation. It is possible that different combinations of Gαi/o-proteins are involved 
in the responses, that the G-protein/effector stoichiometry is different in the pathways 
(Ostrom and Insel, 2004) and that there is cross-talk between the mitogen-activated protein 
kinase and phospholipase A2. In contrast, we studied clearly defined G-protein heterotrimers 
(although at somewhat different GPCR/G-protein ratios) and a proximal parameter of 
GPCR/G-protein coupling, avoiding complications of G-protein/effector stoichiometry and 
cross-talk of signalling pathways. 
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In the study of Krueger et al. (2005), proxyfan exhibited little activity in 
neurotransmitter release assays, full agonism in cAMP accumulation assays and partial 
agonism in [35S]GTPγS binding assays. Additionally, in transfected HEK cells proxyfan 
displayed differential activity in cAMP accumulation- and calcium mobilization assays 
dependent on the type of G protein co-expressed (Gα16 or Gαqi5). The authors concluded that 
the type of G protein determines the pharmacological properties of proxyfan. While it is 
known that Gα16 has an impact on the pharmacological properties of GPCRs (Wenzel-Seifert 
and Seifert, 2000), Gα16 is certainly not a cognate G-protein of hH3R, but rather a G-protein 
expressed in hematopoietic cells and not in neuronal cells (Birnbaumer, 2007). Moreover, 
Gαqi5 is not a physiological G protein, but a chimeric G protein used to direct Gi-coupled 
GPCRs towards Gq- and phospholipase C coupling (Coward et al., 1999). We studied only 
cognate G proteins of hH3R, i.e. Gαi/o-proteins, and did not obtain evidence for ligand-specific 
hH3R conformations. 
Gbahou et al. (2003) expressed H3R in CHO cells. These cells express some of the 
cognate Gαi/o-proteins of H3R, but the specific expression pattern of Gαi/o-subunits was not 
defined in the previous study. Moreover, it is unknown whether the proxyfan-bound H3R 
interacted differentially with various Gαi/o-proteins in CHO cells. Such an interaction can be 
studied by photoaffinity labelling with [α-32P]GTP azidoanilide (Woo et al., 2009). However, 
such data are not available. Moreover, various βxγy-complexes impact on GPCR/G-protein 
coupling (Birnbaumer, 2007). However, in the previous studies on proxyfan βxγy-complexes 
were not defined. We studied a single βγ-complex that is broadly expressed, i.e. β1γ2 
(Birnbaumer, 2007), but we did not examine other βxγy-complexes. It is possible that distinct 
βxγy-complexes account for the protean agonism of proxyfan observed in the previous 
studies, but those βxγy-complexes remain to be identified. It is also possible that differential 
compartmentation of G-protein heterotrimers into specific membrane domains, resulting in 
different GPCR/G-protein stoichiometries (Ostrom and Insel, 2004) contributed to protean 
agonism of proxyfan observed in previous studies. In our co-expression system, we cannot 
exclude different compartmentation of signalling partners either, but the GPCR-Gα fusion 
protein approach circumvented this problem (Seifert et al., 1999b). With hH3R-Gαi/o fusion 
proteins, like with the corresponding co-expression systems, there was no evidence for 
ligand-specific GPCR conformations.  
Another issue is the fact that some of the previous assays were performed with intact 
cells and some assays with membranes. In experiments with intact cells, the precise ionic 
and nucleotide environments of G-proteins are unknown, but both ionic and nucleotide 
composition can largely affect GPCR/G-protein coupling, constitutive GPCR activity and 
pharmacological GPCR profile (Seifert et al., 1999a; Seifert, 2001; Gille et al., 2002). 
Moreover, in intact cells, specifically native tissues, relevant for neutrotransmitter release 
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studies, it cannot be excluded that endogenous histamine is present, thereby changing the 
apparent agonistic/inverse agonistic activities of ligands. We performed experiments with 
extensively washed membranes, excluding the presence of contaminating histamine and 
conducted experiments under clearly defined ionic conditions and nucleotide composition. 
We are aware of the fact that our experimental conditions do not represent physiological 
conditions, but our conditions are defined and allow direct comparison with data from our 
group for other GPCRs over a period of a decade (Seifert et al., 1999a; Seifert, 2001; Gille et 
al., 2002; Preuss et al., 2007; Schneider et al., 2009). Noteworthy, under our experimental 
conditions, different degrees of constitutive activity of a GPCR can be readily detected 
(Seifert, 2001; Wenzel-Seifert and Seifert, 2000; Preuss et al., 2007), supporting the principal 
suitability of our system for the hypothesis tested. 
It should be also noted that the study of Gbahou et al. (2003) was performed with 
rH3R. Species-specific pharmacology of the H3R has been mainly attributed to two aa 
differences in transmembrane domain 3, which are part of the ligand binding site, and this 
leads to changes in antagonist affinities (Yao et al., 2003). However, it is possible that the 
rH3R also shows a different G protein coupling profile compared to the hH3R. Here, we 
studied only the full-length hH3R (445 aa). Future studies will have to examine rH3R as well. 
Another point is the fact that Gbahou et al. (2003) used a truncated splice variant of 
the full-length rH3R (413 aa) in their experiments. This short splice variant lacks 32 amino 
acids in the 3rd intracellular loop of the receptor, which is an important interaction site for G 
proteins (Seifert et al., 1999b; Leurs et al., 2005). It is possible that the truncated rH3R 
possesses an altered G protein coupling profile compared to the full-length rH3R. The 
detailed coupling profiles of various H3R splice variants are not yet known, but should be 
addressed in future investigations. The pattern of H3R splice variant expression differs 
between species and brain regions (Bongers et al., 2007) and splice variants differentially 
regulate signal transduction pathways (Drutel et al., 2001). These data are indicative for 
differences in G protein coupling of H3R splice variants. We studied only the full-length hH3R 
(445 aa) without considering splice variants. 
In conclusion, we have shown that the full-length hH3R (445 aa) couples similarly to 
four defined Gi/Go-protein heterotrimers expressed in Sf9 cells. We did not obtain evidence in 
favor of the hypothesis that proxyfan or eight other H3R ligands are functionally selective in a 
co-expression and a fusion protein system. Moreover, we did not find differences in 
constitutive activity of hH3R under various experimental conditions. These “negative” results 
cannot be attributed to unsuitability of our expression system for exclusion of ligand 
functional selectivity. However, our system is not suitable to definitely exclude protean 
agonism at hH3R, since that would require a systematic and precise variation of receptor-to-
G protein stoichiometries (Kenakin 2001, 2007). Additionally, we discussed several 
Chapter 2: No functional selectivity of proxyfan at hH3R 
 
59 
possibilities that could account, fully or partially, for the differences between the results of our 
study and the previous studies of Gbahou et al. (2003) and Krueger et al. (2005). Extensive 
systematic studies under clearly defined experimental conditions are required to reconcile 
the discrepancies. Thus, presently, a specific and generally applicable mechanistic 
explanation for the previously observed pleiotropic effects of proxyfan cannot yet be 
provided. 
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3.1 Abstract 
 
Ligand pharmacology at histamine H3-receptors is species-dependent. In previous 
studies, two amino acids in transmembrane domain 3 (TM III) were shown to play a 
significant role. In this study, we characterized human and rat histamine H3-receptors (hH3R 
and rH3R, respectively), co-expressed with mammalian G proteins in Sf9 insect cell 
membranes. We compared a series of imidazole-containing H3R ligands in radioligand 
binding and steady-state GTPase assays. H3Rs similarly coupled to Gαi/o-proteins. Affinities 
and potencies of the agonists histamine, Nα-methylhistamine and R-(α)-methylhistamine were 
in the same range. Imetit was only a partial agonist. The pharmacology of imetit and proxyfan 
was similar at both species. However, impentamine was more potent and efficacious at rH3R. 
The inverse agonists ciproxyfan and thioperamide showed higher potency but lower efficacy 
at rH3R. Clobenpropit was not species-selective. Strikingly, imoproxifan was almost full 
agonist at hH3R, but an inverse agonist at rH3R. Imoproxifan was docked into the binding 
pocket of inactive and active hH3R- and rH3R-models and molecular dynamic simulations 
were performed. Imoproxifan bound to hH3R and rH3R in E-configuration, which represents 
the trans-isomer of the oxime-moiety as determined in crystallization studies, and stabilized 
active hH3R-, but inactive rH3R-conformations. Large differences in electrostatic surfaces 
between TM III and TM V cause differential orientation of the oxime-moiety of imoproxifan, 
which then differently interacts with the rotamer toggle switch Trp6.48 in TM VI. Collectively, 
the substantial species differences at H3Rs are explained at a molecular level by the use of 
novel H3R active-state models. 
 
 
3.2 Introduction 
 
 Histamine (HA) exhibits its biological effects through the activation of four different G 
protein-coupled receptors (GPCRs). The histamine H1-receptor (H1R) is associated with 
inflammatory and allergic reactions, e. g. it increases vascular permeability and NO 
production (Hill et al., 1997). The histamine H2-receptor (H2R) regulates gastric acid 
production, but also shows a positive inotropic effect on the heart (Hill et al., 1997). The 
histamine H3-receptor (H3R) is a presynaptic auto- and heteroreceptor, regulating the release 
of HA and various other neurotransmitters in the nervous system, and is involved in 
important physiological processes like the sleep-wake cycle, eating behaviour and cognition 
(Leurs et al., 2005). The histamine H4-receptor (H4R) mediates inflammatory and 
immunological processes, e. g. chemotaxis of eosinophils, mast cells and dendritic cells, but 
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it is also present on neurons mediating HA-induced itching (Leurs et al., 2009; Zampeli and 
Tiligada, 2009). H1R and H2R antagonists have been used as therapeutics for decades, H3R 
and H4R are still explored and promising new drug targets (Tiligada et al., 2009). 
 The H3R was pharmacologically identified in the early 1980s, but cloned almost 20 
years later in 1999 as an orphan GPCR (Leurs et al., 2005). The reason for this delay was 
that it only shares ~20% homology to the H1R and H2R. The complex gene structure of the 
human H3R (hH3R) gives rise to many possible splice variants. To date about 20 hH3R splice 
variants are known (Bongers et al., 2007a), but their function still remains elusive. The H3R 
displays high constitutive, i. e. ligand-independent, activity in many experimental systems 
(Arrang et al., 2007). The H3R is one of the very few GPCRs for which constitutive activity 
has also been demonstrated in vivo (Morisset et al., 2000). 
 For the H3R it has also been shown that species-differences exist (Ireland-Denny et 
al., 2001; Wulff et al., 2002). Fig. 3.1 shows the amino acid sequences of hH3R and rH3R. 
Although the H3R sequence has a high degree of similarity among species, differences 
located in key regions of the receptor protein account for differences in antagonist affinity 
(Ligneau et al., 2000; Yao et al., 2003). Additionally, splice variants differ in composition and 
expression pattern between species, and there are potential differences in signal 
transduction processes between either tissues and/or species (Hancock et al., 2003). 
Nevertheless, there are still unresolved questions about species differences of the full-length 
and un-spliced H3Rs (445 amino acids), especially regarding the detailed molecular 
mechanisms involved in ligand-receptor interactions. 
 In the present study, we systematically compared the pharmacological properties of 
hH3R and rH3R. Fig. 3.2 shows the structures of the compounds studied, all of them being 
imidazole-containing ligands. We co-expressed hH3R and rH3R in Sf9 cells together with 
mammalian G proteins in a defined stoichiometry, determined the affinity of ligands in 
radioligand binding studies, and their potency and efficacy in steady-state GTPase assays. 
The baculovirus/Sf9 cell system is very suitable for the analysis of Gi/Go-coupled receptors 
and in particular constitutively active receptors, because in Sf9 cells no endogenous Gi/Go-
proteins or GPCRs with constitutive activity are present. The controlled expression of 
receptor and G proteins in Sf9 cell membranes represents more the physiological situation 
than, for example, the construction of GPCR-Gα fusion proteins, because fusion proteins do 
not exist physiologically and the mobility of the G proteins is not restricted in the co-
expression system. Moreover, the use of very proximal read-outs, like radioligand binding or 
steady-state GTPase assays prevent possible bias in later steps of the signal transduction 
cascade. 
 Many studies of ligand-receptor interactions come to a point where structural 
information on the atomic level is needed to explain experimental results. In the case of 
Chapter 3: Species differences of hH3R and rH3R 
 
66 
GPCRs, this is a very challenging and time-consuming process, and at the end only 
snapshots of static ligand-receptor complexes are resolved (Kobilka and Schertler, 2008). 
However, more and more high-resolution crystal structures of inactive- and active-state 
GPCR-ligand complexes are becoming available and can be used to generate better 
homology models (Rasmussen et al., 2007; Jaakola et al., 2008; Park et al., 2008). Since 
active-state models for H3Rs do not yet exist, we generated and used those models to 
explain the pharmacological species differences at hH3R and rH3R on the basis of 
experimental data. These new models combine the information of previous studies on H3Rs 
(Schlegel et al., 2007), and were complemented with sophisticated studies on the activation 
process of H1Rs (Strasser and Wittmann, 2007; Strasser et al., 2009). 
 
 
3.3 Materials and Methods 
 
3.3.1 Materials 
The cDNAs of the hH3R and rH3R were kindly provided by Dr. T. Lovenberg (Johnson 
& Johnson Pharmaceutical R&D, San Diego, CA, USA). An alignment of the corresponding 
amino acid sequences is given in Fig. 3.1. Anti-hH3R Ig and anti-rH3R Ig were from Bio-Trend 
(Cologne, Germany). The antibody recognizing both species homologs was from GeneWay 
(San Diego, CA, USA). All other antibodies, purified G proteins, reagents for molecular 
biology, recombinant baculoviruses encoding mammalian G protein subunits, and the 
sources of test compounds were described before (Schnell et al., 2009). Chemical structures 
of H3R ligands are depicted in Fig. 3.2. Stock solutions (10 mM) of all H3R ligands described 
in this paper were prepared in distilled water and stored at -20°C. [3H]JNJ-7753707 (= 
[3H]RWJ-422475) (30 Ci/mmol) was kindly donated from Dr. P. Bonaventure (Johnson & 
Johnson Pharmaceutical R&D, San Diego, CA, USA). [3H]Nα-methylhistamine (74-85 
Ci/mmol) and [35S]GTPγS (1100 Ci/mmol) were obtained from Perkin Elmer (Boston, MA, 
USA). [γ-32P]GTP was synthesized as described (Schnell et al., 2009). Unlabeled nucleotides 
were from Roche (Indianapolis, IN, USA) and all other reagents were of the highest purity 
available and from standard suppliers. 
 
3.3.2 Construction of FLAG epitope- and hexahistidine-tagged cDNAs for hH3R and 
rH3R 
The cDNA for the tagged rH3R protein was generated by sequential overlap-extension 
PCR in analogy to the procedure described recently for hH3R (Schnell et al., 2009). In the 
case of rH3R, the sense primer RAT HRH3-F- (5´- GAC GAT GAT GAC GCC ATG GAG 
CGC GCG CCG CC-3´) consisted of 15 bp of the 3’-end of SF and the first 17 bp of the 5’-
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end of the rH3R. The antisense primer RAT HRH3-RV (5´- GA TCC TCT AGA TTA GTG 
ATG GTG ATG ATG GTG CTT CCA GCA CTG CTC -3´) consisted of 15 bp of the C-
terminus of the rH3R, and encoded a hexahistidine tag, the stop codon, and a Xba I site. As 
template, a plasmid (pCIneo) containing the sequence of rH3R was used. 
 
3.3.3 Generation of recombinant baculoviruses, cell culture and membrane 
preparation, SDS-PAGE and immunoblot analysis 
The protocols for virus amplification, protein expression and western blot analysis 
were described before (Schnell et al., 2009). Proteins transferred to nitrocellulose 
membranes were reacted with anti-hH3R (N-term) (1:1000), anti-rH3R (C-term) (1:1000) and 
anti-H3R (i3) (1:1000) Igs. 
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Fig. 3.1. Comparison of the amino acid sequences of hH3R (GeneBank Accession No. 
AF140538) and rH3R (GeneBank Accession No. AF237919). Putative transmembrane 
domains are stated above the sequences and indicated by a solid line. N-term, extracellular 
N-terminal domain of H3Rs; C-term, intracellular C-terminal domain of H3Rs; i1, i2, and i3, 
first, second, and third intracellular loops; e1, e2, e3, first, second, and third extracellular 
loops, respectively. Dots in the sequence of rH3R indicate identity with hH3R. Amino acids 
shown in regular fonts in the sequence of rH3R represent conservative differences, those 
shown in bold represent non-conservative differences. The most conserved residues in each 
TM domain are indicated in grey shading. Residues within TM domains are named according 
to the Ballesteros/Weinstein nomenclature. The most conserved residue in each TM is 
numbered as X.50, where X is the number of the respective TM domain (Ballesteros and 
Weinstein, 1995). Amino acids shown in white with black shading represent a putative 
glycosylation site of the H3R. Amino acids in frame represent putative interaction sites of HA 
with the H3R (Uveges et al., 2002; Yao et al., 2003). 
 
 
3.3.4 [35S]GTPγS saturation binding assay 
Experiments were performed in analogy to the assay described in Schnell et al. 
(2009). Membranes were thawed and sedimented by a 10-min centrifugation at 4°C and 
15,000g to remove residual endogenous guanine nucleotides as far as possible. Membranes 
were resuspended in binding buffer (12.5 mM MgCl2, 1 mM EDTA, and 75 mM Tris-HCl, pH 
7.4), supplemented with 0.05% (m/v) BSA. Each tube (total volume of 250 or 500 µl) 
contained 10 - 20 µg of membrane protein. Tubes contained 0.2 – 2 nM [35S]GTPγS plus 
unlabeled GTPγS to give the desired final ligand concentrations (0.2 – 50 nM). Neither GDP 
nor H3R ligands were included in assays. Non-specific binding was determined in the 
presence of 100 µM unlabeled GTPγS and amounted to less than 1% of total binding. 
Incubations were conducted for 90 minutes at 25°C and shaking at 250 rpm. Bound 
[35S]GTPγS was separated from free [35S]GTPγS by filtration through GF/C filters, followed by 
three washes with 2 ml of binding buffer (4°C). Filter-bound radioactivity was determined by 
liquid scintillation counting. The experimental conditions chosen ensured that not more than 
10 % of the total amount of radioactivity added to binding tubes was bound to filters. The 
maximum number of Gαi/o-related GTPγS binding sites in membranes expressing H3Rs plus 
Gα-subunits plus β1γ2 was corrected by the binding determined in parallel in membranes 
expressing H3Rs plus β1γ2 alone. These reference membranes were always prepared under 
exactly the same conditions as the other ones. To ensure the same viral load in the 
reference membranes, Sf9 cells were infected with baculoviruses encoding H3Rs, β1γ2 and 
virus encoding no recombinant protein at all. In this manner, only the number of functionally 
intact and heterologously expressed mammalian Gαi/o-subunits was quantitated. 
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Fig. 3.2. Structures of imidazole-containing H3R-ligands: full agonists 1-3, partial 
agonists 4-6, imoproxifan 7, and antagonists/inverse agonists 8-10. 
 
 
3.3.5 Steady-state GTPase activity assay 
Experiments were performed in analogy to the assay described in Schnell et al. 
(2009). Briefly, membranes were thawed, sedimented and resuspended in 10 mM Tris/HCl, 
pH 7.4. Assay tubes contained Sf9 membranes (10 – 20 µg of protein/tube), 5.0 mM MgCl2, 
0.1 mM EDTA, 0.1 mM ATP, 100 nM GTP, 0.1 mM adenylyl imidodiphosphate, 1.2 mM 
creatine phosphate, 1 µg of creatine kinase, and 0.2% (w/v) bovine serum albumin in 50 mM 
Tris/HCl, pH 7.4, and H3R ligands at various concentrations. Reaction mixtures (80 µl) were 
incubated for 2 min at 25°C before the addition of 20 µl of [γ-32P]GTP (0.1 µCi/tube). All stock 
and work dilutions of [γ-32P]GTP were prepared in 20 mM Tris/HCl, pH 7.4. Reactions were 
conducted for 20 min at 25°C. Reactions were terminated by the addition of 900 µl of slurry 
consisting of 5% (w/v) activated charcoal and 50 mM NaH2PO4, pH 2.0. Charcoal absorbs 
nucleotides but not Pi. Charcoal-quenched reaction mixtures were centrifuged for 7 min at 
room temperature at 15,000g. Six hundred microliters of the supernatant fluid of reaction 
mixtures were removed, and 32Pi was determined by liquid scintillation counting. Enzyme 
activities were corrected for spontaneous degradation of [γ-32P]GTP. Spontaneous [γ-
32P]GTP degradation was determined in tubes containing all of the above described 
components plus a very high concentration of unlabeled GTP (1 mM) that, by competition 
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with [γ-32P]GTP, prevents [γ-32P]GTP hydrolysis by enzymatic activities present in Sf9 
membranes. Spontaneous [γ-32P]GTP degradation was <1% of the total amount of 
radioactivity added using 20 mM Tris/HCl, pH 7.4, as solvent for [γ-32P]GTP. The 
experimental conditions chosen ensured that not more than 10% of the total amount of [γ-
32P]GTP added was converted to 32Pi. 
 
3.3.6 Radioligand binding assays 
Experiments were performed in analogy to the assay described in Schnell et al. 
(2009). Membranes were thawed and sedimented by a 10-min centrifugation at 4°C and 
15,000g and resuspended in binding buffer (12.5 mM MgCl2, 1 mM EDTA, and 75 mM Tris-
HCl, pH 7.4), to remove residual endogenous guanine nucleotides as much as possible. In 
[3H]NAMH binding assays, each tube (total volume, 250 or 500 µl) contained 10 to 50 µg of 
protein. Non-specific binding was determined in the presence of [3H]NAMH at various 
concentrations plus 10 µM THIO and amounted to ~10% of total binding at saturating 
concentrations (10 nM). Incubations were conducted for 60 min at RT and shaking at 250 
rpm. Saturation binding experiments were carried out using 0.3 to 10 nM [3H]NAMH in the 
presence or absence of 10 µM GTPγS. In competition binding experiments, tubes contained 
1 nM [3H]NAMH and unlabeled ligands at various concentrations. Bound [3H]NAMH was 
separated from free [3H]NAMH by filtration through GF/C filters pretreated with 0.3% (m/v) 
polyethyleneimine, followed by three washes with 2 ml of binding buffer (4°C). [3H]JNJ-
7753707 (= [3H]RWJ-422475) binding experiments were performed using the same 
procedure as described above for [3H]NAMH. With [3H]JNJ-7753707 as radioligand, non-
specific binding was about 20-30% of total binding at saturating concentrations (10 nM). 
Filter-bound radioactivity was determined by liquid scintillation counting. The experimental 
conditions chosen ensured that not more than 10 % of the total amount of radioactivity added 
to binding tubes was bound to filters. 
 
3.3.7 Construction of inactive and active models of hH3R and rH3R 
Based on the crystal structure of the human β2-adrenergic receptor (Cherezov et al., 
2007; Rasmussen et al., 2007), a homology model of the inactive rH3R was generated. 
Based on the active state model of guinea pig H1R (gpH1R) (Strasser and Wittmann, 2007; 
Strasser et al., 2008b), an active model of hH3R was constructed by homology modelling. All 
models were refined and energetically minimized with SYBYL 7.0 (Tripos, St. Louis, MO), as 
described (Igel et al., 2009). Imoproxifan was docked manually into the binding pocket of the 
active hH3R and the inactive rH3R. Thereby, previous results of similar compounds were 
taken into account (Schlegel et al., 2007). The resulting structures were embedded in a 
simulation box, including lipid bilayer, water, sodium and chlorine ions, as described 
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(Strasser et al., 2008a). Subsequently, molecular dynamic simulations with GROMACS 3.3.1 
(van der Spoel et al., 2004) were performed, using a simulation protocol, previously 
described (Strasser et al., 2008a). 
 
3.3.8 Miscellaneous 
Molecular biology was planned with GCK 2.5 (Textco BioSoftware, West Lebanon, 
NH, USA). Ligand structures were illustrated using ChemDraw Ultra 8.0 (CambridgeSoft, 
Cambridge, MA, USA). The sequence alignment was performed using ClustalX (2.0), which 
is a windows interface based on the Clustal W algorithm (Thompson et al., 1994). Protein 
was determined using the DC protein assay kit (Bio-Rad, Hercules, CA, USA). 
[3H]Dihydroalprenolol was obtained from Perkin Elmer (Boston, MA, USA) and protein 
quantification via western blot performed as described in Schnell et al. (2009). All analyses of 
experimental data were performed with the Prism 5 program (GraphPad Software, San 
Diego, CA, USA). 
 
 
3.4 Results 
 
3.4.1 Western blot analysis of hH3R and rH3R expressed in Sf9 insect cell membranes 
Membranes of Sf9 cells expressing hH3R or rH3R plus mammalian G proteins were 
prepared and analyzed via immunoblot. It has to be mentioned, that membranes co-
expressing rH3R plus different mammalian G proteins were prepared in parallel and under 
exactly the same conditions as the membranes expressing hH3R (Schnell et al., 2009). Thus, 
the comparison of hH3R and rH3R pharmacology in this system is not based on historical 
data but direct. Both hH3R and rH3R bands were doublets, probably representing differently 
glycosylated forms (Fig. 3.3). H3R species homologs presumably exhibit similar glycosylation 
patterns since the putative N-glycosylation site for the H3R (Asn11) is fully conserved within 
their sequences (Fig. 3.1). The H3R species homologs could be clearly discriminated by anti-
hH3R Ig, raised against an 18 amino acid peptide within the extracellular N-terminus of the 
hH3R, and anti-rH3R Ig, raised against an 18 amino acid peptide within the cytoplasmatic C-
terminus of the rH3R (Figs. 3.3A and 3.3B). 
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Fig. 3.3. Immunological detection of hH3R and rH3R expressed in Sf9 cells. Each lane of 
the gels was loaded with 10 µg of membrane protein, unless otherwise indicated below the 
film. Numbers on the left designate masses of marker proteins in kDa. In A and B, 
membranes expressing the hH3R and rH3R alone were loaded onto the gels. Proteins 
separated in A were reacted with anti-hH3R Ig and in B with anti-rH3R Ig. In C, membranes of 
A and B plus control were analyzed. Here, the proteins were reacted with the non-species-
selective anti-hH3R (i3) Ig. In D1 and D2, 2, 4, 6, 8 and 10 µg of protein of Sf9 membranes 
expressing hβ2AR at 7.5 pmol/mg (as determined by [³H]dihydroalprenolol saturation binding) 
were used as standard to assess the expression levels of the rH3R in different membrane 
preparations with anti-FLAG Ig. In E, the same membranes were reacted with anti-His6 Ig. In 
F, the membranes were reacted with anti-Gαi-common Ig. In G, the membranes were reacted 
with anti-Gβ-common Ig. In H, 0.5, 1.0, 1.5 and 2.0 µg of a membrane expressing the rH3R + 
Gαi2 + β1γ2 was analyzed in order to quantify the Gα-subunits, using 2, 4, 7.5, 15 and 30 pmol 
of purified Gαi2 as standard. In I, 0.5, 1.0, 1.5 and 2.0 µg of a corresponding membrane of the 
same batch expressing rH3R + Gαo1 + β1γ2 was analyzed to quantify the Gα-subunits, using 2, 
4, 7.5, 15 and 30 pmol of purified Gαo2 an almost identical splice variant of Gαo1 as standard. 
 
 
Additionally, anti-H3R (i3) Ig was used to confirm the above mentioned results (Fig. 
3.3C). This antibody was raised against a peptide sequence within the third intracellular loop 
(i3) of the hH3R, but turned out to be not species-selective. Again, all H3R bands occurred as 
doublets at ~49 kDa. However, there were some additional bands at lower molecular weight, 
which are presumably non-specific, since they also appeared at the control lane loaded with 
uninfected Sf9 cell membranes. Thus, our data indicate that hH3R and rH3R were equally 
well and properly expressed in Sf9 cells. In analogy to our recent publication (Schnell et al., 
2009), the rH3R was also co-expressed with different mammalian G proteins (Gαi1, Gαi2, Gαi3 
or Gαo1, and β1γ2 dimers, respectively) to analyze the coupling profile. All proteins were 
properly detected by different selective antibodies (Fig. 3.3). Moreover, we also quantified 
the expression levels of receptors and G proteins by immunoblot, using hβ2AR or purified G 
protein subunits as standards (Fig. 3.3D and 3.3H, I). The results of these studies are 
summarized in Table 3.1. 
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3.4.2 Quantitative analysis of receptor-to-G protein stoichiometries 
Protein quantification via western blot is semi-quantitative and does not discriminate 
between functional and non-functional proteins. Therefore, we directly used a recently 
described combination of antagonist [³H]JNJ-7753707- and [35S]GTPγS-saturation binding 
(Schnell et al., 2009) and calculated the functional GPCR/Gα protein ratios (Table 3.1). 
Similar to the membranes expressing hH3R, we detected an excess of mammalian G 
proteins in the case of rH3R, confirming the previously reported results (Schnell et al., 2009). 
Thus, G protein expression level is not limiting in this experimental system, too. 
 
3.4.3 hH3R and rH3R coupling to different Gα-subunits 
The G protein coupling profile of rH3R (Table 3.2) was also investigated as for the 
hH3R (Schnell et al., 2009). Briefly, receptor-dependent [γ-
32P]GTP hydrolysis of different Gα-
subunits was measured under steady-state conditions. GTPase activities were determined in 
parallel under basal conditions, maximal stimulation with the physiological (and full) agonist 
histamine (10 µM) and a saturating concentration of the inverse agonist thioperamide (10 
µM) in Sf9 cell membranes co-expressing the rH3R and different G proteins. 
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Table 3.1: Quantification of rH3R-to-G protein ratios via western blot, [³H]JNJ-7753707- 
and [35S]GTPγS-saturation binding. 
 
 Bmax ± S. E. M. (pmol × mg
-1) 
rH3R + β1γ2 
membrane 
+ Gαi1 + Gαi2 + Gαi3 + Gαo1 
immunoblot: 
anti-FLAG Ig 
~1.5 – 2.5 ~1.5 – 2.5 ~1.5 – 2.5 ~1.5 – 2.5 
anti-Gα Igs n. d. ~50 - 100 n. d. ~50 - 100 
[³H]JNJ-7753707 0.67 ± 0.03 0.77 ± 0.02 1.05 ± 0.04 1.25 ± 0.04 
[35S]GTPγS 3.40 ± 0.80 4.43 ± 0.53 2.52 ± 0.37 8.19 ± 1.27 
R : G ratio ~1 : 5 ~1 : 6 ~1 : 2 ~1 : 7 
 
The quantification of receptors and G proteins via immunoblot was performed as described in 
Schnell et al. (2009). [³H]JNJ-7753707 saturation bindings were performed as described 
under Methods. [35S]GTPγS saturation bindings were performed, using Sf9 cell membranes 
from the same batch of preparation. Reaction mixtures contained membranes (10 - 20 µg of 
protein), 0.2 - 2 nM of [35S]GTPγS, and unlabeled GTPγS to give the desired final ligand 
concentrations for saturation (0.2 – 50 nM). GDP or additional H3R ligands were not present 
in the reaction mixtures. Data were analyzed by nonlinear regression and were best fitted to 
hyperbolic one-site saturation isotherms. The maximal number of GTPγS binding sites in 
membranes expressing rH3R plus Gαi2 plus β1γ2 was corrected by the binding determined in 
rH3R plus β1γ2. By this way, the number of functionally intact and heterologously expressed G 
protein α-subunits was quantified. Data shown are the means ± S. E. M. of 3 independent 
experiments performed in triplicate. Receptor-to-G protein ratios were calculated, using the 
Bmax values determined for the different membrane preparations. 
 
 
Like hH3R, rH3R coupled efficiently to all co-expressed mammalian Gαi/o-subunits 
(Gαi1, Gαi2, Gαi3 or Gαo1, and β1γ2 dimers, respectively), as was evident by the high basal 
GTPase activities and the large absolute stimulatory and inhibitory effects of histamine and 
thioperamide, respectively (Table 3.2). Also, the relative stimulatory effects of histamine and 
the relative inhibitory effects of thioperamide based on total ligand-regulated GTPase activity 
were similar for each of the four systems studied, indicating that the constitutive activity of 
rH3R was comparable and not substantially influenced by the type of G protein (Table 3.2). 
The constitutive activity of rH3R coupled to cognate Gi/Go-proteins was rather high and 
comparable to the constitutive activity of hH3R, rendering the two systems suitable for an 
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analysis of species-specific ligand effects, without possible bias due to differences in basal 
activity between membranes. 
 
Table 3.2: Analysis of rH3R/G protein coupling - GTPase activities in Sf9 membranes 
expressing rH3R and different Gαi/o-proteins. 
 
rH3R + β1γ2 
GTPase activity 
± S. E. M. 
 + Gαi1 + Gαi2 + Gαi3 + Gαo1 
basal 
(pmol × mg-1 × min-1) 
 1.22 ± 0.21 1.75 ± 0.22 1.12 ± 0.04 4.29 ± 0.12 
+ ago. 
(pmol × mg-1 × min-1) 
 2.01 ± 0.26 3.17 ± 0.37 2.13 ± 0.14 5.95 ± 0.14 
∆ ago. 
(pmol × mg-1 × min-1) 
 0.79 ± 0.07 1.42 ± 0.15 1.01 ± 0.10 1.66 ± 0.09 
Agonist stimulation 
(% of basal) 
 67.44 ± 0.09 81.78 ± 2.32 89.38 ± 5.14 38.78 ± 2.38 
+ inv. ago. 
(pmol × mg-1 × min-1) 
 0.71 ± 0.10 0.85 ± 0.12 0.59 ± 0.03 2.86 ± 0.14 
∆ inv. ago. 
(pmol × mg-1 × min-1) 
 0.51 ± 0.13 0.90 ± 0.10 0.53 ± 0.02 1.43 ± 0.13 
Inverse agonist 
inhibition 
(% of basal) 
 40.32 ± 5.93 51.66 ± 0.96 47.4 ± 0.82 33.29 ± 2.88 
 
Steady-state GTPase experiments were performed as described in Methods. Reaction 
mixtures contained 0.1 µCi [γ-32P]GTP and 100 nM unlabeled GTP in the presence of solvent 
(basal), 10 µM HA (+ ago.) or 10 µM THIO (+ inv. ago.). Data shown are the means ± S. E. 
M. of three to four independent experiments for each membrane preparation performed in 
duplicates. The absolute agonist-stimulation (∆ ago.) and inverse agonist-inhibition (∆ inv. 
ago.) of GTP hydrolysis, as well as the relative agonist-stimulation and inverse agonist-
inhibition of GTP hydrolysis (% of basal), were calculated. 
 
 
 
 
Chapter 3: Species differences of hH3R and rH3R 
 
78 
3.4.4 Ligand potencies and efficacies in the steady-state GTPase assay at rH3R 
compared to hH3R co-expressed with different Gα-subunits 
Next, we examined a series of imidazole-based ligands in Sf9 cell membranes 
expressing rH3R and different Gαi/o-proteins in the steady-state GTPase assay. The data 
(Table 3.3) were then compared with the results for hH3R (Schnell et al., 2009). 
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Fig. 3.4. Comparison of the effects of histamine, imoproxifan and thioperamide in 
membranes co-expressing the hH3R or rH3R, Gαi2 subunits and β1γ2 dimers. Steady-
state GTPase activity in Sf9 membranes was determined as described under Methods. 
Reaction mixtures contained HA, IMO or THIO at the concentrations indicated on the 
abscissa to achieve saturation. Data are expressed as percentage change in GTPase 
activity induced by the ligands compared to the GTPase activity stimulated by HA (10 µM), 
which was defined to be 100%. Data were analyzed by nonlinear regression and were best fit 
to sigmoidal concentration/response curves. Data points shown are the means ± S. E. M. of 
3 - 4 independent experiments performed in duplicate. A summary of all results is shown in 
Table 3.3. 
 
 
The endogenous agonist histamine (1) and the standard H3R ligands N
α-
methylhistamine (2) and (R)-α-methylhistamine (3) were full agonists and equally potent in all 
membranes. There were essentially no species-differences. The highly potent standard H3R 
agonist imetit (4) was almost a full agonist at rH3R, too. Interestingly, proxyfan (5) was again 
a strong partial agonist in all systems, independent of the G protein subtype co-expressed, 
corroborating the notion that this ligand does not show functional selectivity at H3Rs (Schnell 
et al., 2009). In contrast to hH3R, impentamine (6) was a strong and more potent partial 
agonist at rH3R in all experimental settings. Strikingly, imoproxifan (7) was an inverse agonist 
at rH3R, but almost full agonist at hH3R (Fig. 3.4). The type of G protein subunit did not 
change the pharmacological profile of imoproxyfan (Table 3.3). The inverse agonists 
ciproxyfan (8) and thioperamide (10) were more potent but less efficacious at rH3R than at 
hH3R and again, the G protein subtype caused no changes in their profiles. Clobenpropit (9) 
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was neither species-specific nor did the G protein subtype change its pharmacology. 
Moreover, there is also a strong linear correlation between potencies and efficacies of 
imidazole-based ligands at membranes expressing rH3R and different Gαi/o-subunits, as was 
found for the hH3R (Fig. 3.5; Table 3.3). Thus, the pharmacological profile of the rH3R is also 
very similar under the various experimental conditions and, like at hH3R, ligand-specific 
receptor conformations leading to coupling differences do not exist for the compounds 
investigated (Schnell et al., 2009). 
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Fig. 3.5. Correlation of potency and efficacy of ligands at the rH3R in the presence of 
different co-expressed Gαi/o-proteins. Data shown in Table 3.3 were analyzed by linear 
regression. Numbers designate individual ligands decoded in Fig. 3.2. In A, C and E, the 
potencies of ligands at membranes co-expressing the rH3R, Gαi1, Gαi3 or Gαo1, and β1γ2-
dimers, respectively, were correlated with values determined at the reference membrane 
expressing Gαi2. A, r
2 = 0.77; slope = 0.99 ± 0.19. C, r2 = 0.97; slope = 1.17 ± 0.07. E, r2 = 
0.96; slope = 1.05 ± 0.07. In B, D and F, the efficacies of ligands at membranes co-
expressing the rH3R, Gαi1, Gαi3 or Gαo1, and β1γ2 dimers, respectively, were correlated with 
values determined at the reference membrane expressing Gαi2. B, r
2 = 0.99; slope = 0.97 ± 
0.04. D, r2 = 0.96; slope = 0.99 ± 0.07. F, r2 = 0.996; slope = 1.20 ± 0.03. The dotted lines 
indicate the 95% confidence intervals of the regression lines. The diagonal dashed line has a 
slope of 1 and represents a theoretical curve for identical values. 
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Collectively, these results confirm the findings regarding the relative stimulatory and 
inhibitory effects of histamine and thioperamide, respectively (Table 3.2), based on total 
ligand-regulated GTPase activity and are indicative for similar constitutive activity of hH3R 
and rH3R under all experimental conditions. If there had been differences in constitutive 
activity between hH3R and rH3R, then systematic changes in the potencies of full agonists as 
well as potencies and efficacies of partial agonists and inverse agonists would have 
occurred. This, however, was not the case. In contrast, the behaviour of ligands, e. g. 
impentamine or imoproxifan, at one H3R species homolog often opposed each other, against 
every expectation. Thus, these ligand effects are solely species-specific and not due to 
differences in constitutive activity of hH3R and rH3R. 
 
3.4.5 [3H]NAMH binding studies at hH3R and rH3R 
Since the type of G protein co-expressed did not change the pharmacology of ligands 
at both hH3R and rH3R in the steady-state GTPase assay, we performed radioligand binding 
experiments for a further characterization only at membranes expressing hH3R or rH3R plus 
Gαi2 plus β1γ2 dimers. 
At first, we addressed the formation of a high-affinity ternary complex between the 
agonist [3H]NAMH, the hH3R or rH3R and nucleotide-free G protein in saturation binding 
experiments (Fig. 3.6). The Kd of [
3H]NAMH at hH3R was 0.62 ± 0.21 nM (n = 3). At rH3R, the 
Kd value was 1.37 ± 0.36 nM (n = 3). Interestingly, binding of [
3H]NAMH was only partially 
GTPγS-sensitive in both cases. The Kd values of [
3H]NAMH in the presence of GTPγS (10 
µM) were about 2-fold lower, but the Bmax values did not change significantly (Fig. 3.6). 
In competition binding experiments (Fig. 3.7), histamine (1), Nα-methylhistamine (2), 
(R)-α-methylhistamine (3), imetit (4) and proxyfan (5) had essentially the same affinities at 
hH3R and rH3R. Impentamine (6), imoproxifan (7), ciproxyfan (8) and thioperamide (10) 
bound with higher affinity to rH3R. Clobenpropit (9) also bound with similar affinity to both 
receptors. The pharmacological profiles, determined in [3H]NAMH competition binding (Table 
3.4) and steady-state GTPase assays (Table 3.3), compared with the literature, were very 
similar (Lim et al., 2005; Bongers et al., 2007b). 
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Fig. 3.6. [3H]NAMH saturation bindings in Sf9 cell membranes expressing hH3R or rH3R 
in combination with Gαi2 and β1γ2. Experiments were performed as described under 
Methods. Data were analyzed by nonlinear regression and were best fitted to hyperbolic one-
site saturation isotherms. The closed circles (●) show the data for the specific [3H]NAMH 
binding in the absence of GTPγS (10 µM), the open circles (○) in the presence of GTPγS (10 
µM). In A, hH3R was analyzed and in B, rH3R was analyzed. Data points shown are the 
means ± S. E. M. of 3 independent experiments performed in triplicate, using three different 
membrane preparations. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.7. Competition of [3H]NAMH binding by histamine, imoproxifan and 
thioperamide in Sf9 membranes expressing hH3R and rH3R in combination with Gαi2 
and β1γ2. [
3H]NAMH binding was determined as described under Methods. Reaction mixtures 
contained Sf9 membranes (10 - 50 µg of protein per tube) expressing the recombinant 
proteins, 1 nM [3H]NAMH, and ligands at the concentrations indicated on the abscissa. A, 
competition binding at hH3R and B, competition binding at rH3R. Data were analyzed for best 
fit to monophasic competition curves (F test). Data points shown are the means ± S. E. M. of 
3 - 5 independent experiments performed in duplicate. A summary of all results is shown in 
Table 3.7. 
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Table 3.4: [³H]NAMH competition bindings in Sf9 membranes expressing hH3R or rH3R 
in combination with Gαi2 and β1γ2. 
 
 pKi ± S. E. M. 
 hH3R + Gαi2 + β1γ2 rH3R + Gαi2 + β1γ2 
HA 8.20 ± 0.04 7.89 ± 0.07 
NAMH 9.22 ± 0.03 8.70 ± 0.09 
RAMH 8.91 ± 0.07 8.62 ± 0.07 
IME 9.20 ± 0.05 9.38 ± 0.08 
PRO 7.87 ± 0.07 8.08 ± 0.10 
IMP 8.84 ± 0.06 10.11 ± 0.05 
IMO 6.92 ± 0.06 8.47 ± 0.09 
CIP 7.03 ± 0.12 8.87 ± 0.08 
CLOB 9.34 ± 0.06 9.11 ± 0.06 
THIO 7.34 ± 0.04 7.94 ± 0.04 
 
r2 (pKi/pEC50) 0.83 0.50 
slope (pKi/pEC50) 0.94 ± 0.15 0.83 ± 0.29 
 
Experiments were performed as described under Methods. Reaction mixtures contained Sf9 
membranes (10 – 50 µg of protein), 1 nM [³H]NAMH, and unlabeled ligands at concentrations 
of 0.1 nM to 10 µM as appropriate to generate saturated competition curves. Data were 
analyzed by nonlinear regression and were best fit to one-site (monophasic) competition 
curves. Data shown are the means ± S. E. M. of three to five independent experiments 
performed in duplicate at 3 different membrane preparations. Additionally, data shown were 
correlated and analyzed by linear regression. The affinities and potencies of ligands at 
membranes co-expressing the hH3R or rH3R plus Gαi2 plus β1γ2 dimers, respectively, were 
correlated. The correlation coefficients (r2) and the slopes of all tested ligands are presented 
at the bottom of the table. 
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The pKi and pEC50 values determined at hH3R correlated well, suggesting a direct 
signal transfer in the Sf9 cell system (Fig. 3.8). However, at rH3R, the correlation coefficient 
was rather low, due to an extraordinary high affinity of impentamine (6). Interestingly, the pKi 
values of imoproxifan (7) were significantly lower than the corresponding pEC50 values 
determined in the GTPase assay (t test, p < 0.05). 
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Fig. 3.8. Correlation of affinity and potency of ligands at the hH3R and rH3R. Data 
shown were analyzed by linear regression. Numbers designate individual ligands decoded in 
Fig. 3.2. In A, the affinities and potencies of ligands at membranes co-expressing the hH3R, 
Gαi2 and β1γ2 dimers were correlated. A, r
2 = 0.83; slope = 0.94 ± 0.15. In B, the affinities and 
potencies of ligands at membranes co-expressing the rH3R, Gαi2 and β1γ2 dimers were 
correlated. B, r2 = 0.50; slope = 0.83 ± 0.29. The dotted lines indicate the 95% confidence 
intervals of the regression lines. The diagonal dashed line has a slope of 1 and represents a 
theoretical curve for identical values. 
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3.4.6 Binding mode of imoproxifan at hH3R and rH3R 
To understand the molecular basis for the unique behaviour of imoproxifan, we 
performed molecular modelling studies with hH3R and rH3R. The binding modes of 
imoproxifan at active hH3R and inactive rH3R, representing the most favoured ligand-
receptor-complexes, are presented in Fig. 3.9. 
Imoproxifan is bound to hH3R and rH3R in E-configuration, representing the trans-
isomer of the oxime-moiety. The E-configuration was also determined to be the favoured one 
by crystallographic studies (Sasse et al., 2000). The electrostatic surface potential of the 
amino acids with the ligand in the binding pocket is shown (Fig. 3.9, A and B). At hH3R and 
rH3R, the positively charged terminal imidazole moiety of imoproxifan interacts with the highly 
conserved Asp3.32 (Fig. 3.9, A and B, black arrow). However, there are large differences in 
electrostatic surface between TM V and TM III (Fig. 3.9, A and B, yellow, dotted line). In this 
region, the electrostatic surface potential is rather neutral at hH3R, but negatively charged at 
rH3R. The consequence is a different orientation of the oxime moiety of imoproxifan. At 
hH3R, the methyl moiety points upward, whereas at rH3R, the methyl moiety points 
downward. 
The reason for the differences in electrostatic surface potential between hH3R and 
rH3R are explained by the amino acid difference at position 3.37 between hH3R and rH3R. At 
hH3R, Glu
5.46 can electrostatically interact with Thr3.37 (Fig. 3.9, C, yellow, dotted line). Thus, 
Glu5.46 points towards Thr3.37 and away from the binding pocket. Consequently, the 
electrostatic potential surface in this region is neutral. In contrast, at rH3R, Thr
3.37 is 
exchanged into Ala3.37. Thus, an electrostatic interaction between Glu5.46 and the amino acid 
side chain in position 3.37 is no longer possible. Instead, the modelling studies revealed an 
electrostatic interaction of Glu5.46 and Tyr3.33 at rH3R (Fig. 3.9, D, yellow, dotted line). 
Consequently, the negatively charged side chain of Glu5.46 points partially toward the binding 
pocket, resulting in a negative electrostatic potential surface in this region. 
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Fig. 3.9. Binding mode of imoproxifan at the active hH3R and inactive rH3R. 
A, electrostatic potential surface in the binding pocket of active hH3R with imoproxifan in its 
binding conformation. B, electrostatic potential surface in the binding pocket of the inactive 
rH3R with imoproxifan in its binding conformation. A and B, yellow dotted circle: the 
electrostatic potential is rather neutral at hH3R, but negatively charged at rH3R. The 
consequence is a different orientation of the ligands oxime moiety. C, conformation of amino 
acids in the imoproxifan bound state of active hH3R. D, conformation of amino acids in the 
imoproxifan bound state of inactive rH3R. C and D, yellow dotted circle: important differences 
in side chain conformation of Glu5.46 between hH3R and rH3R. At hH3R, Glu
5.46 interacts with 
Thr3.37 and points away from the binding pocket. At rH3R, Thr
3.37 is exchanged to Ala3.37. 
Thus, the interaction between Glu5.46 and the amino acid in position 3.37 is no longer 
possible and Glu5.46 interacts with Tyr3.33. Green dotted circle: in position 3.40, there is a 
small Ala at hH3R, but the more bulky Val at rH3R. It is suggested that this species difference 
is also be important for the different orientations of the oxime moiety between hH3R and 
rH3R. E, interaction between imoproxifan and hH3R; F, interaction between imoproxifan and 
rH3R. E and F, yellow dotted circle: at hH3R, the oxime moiety of imoproxifan points 
downwards and stabilizes the highly conserved Trp6.48 by a hydrogen bond; at rH3R, the 
oxime moiety of imoproxifan points upwards interacts electrostatically with a negatively 
charged surface established by Glu5.46 and Tyr3.33. 
 
 
A second species-difference between hH3R and rH3R near to the binding pocket is 
located at position 3.40. There is an alanine at hH3R, but a bulkier valine at rH3R (Fig. 3.9, C 
and D, green, dotted line). It is likely that this amino acid difference also directs the oxime 
moiety of imoproxifan into a distinct orientation. Since Ala3.40 is not as bulky as Val3.40, there 
is more space for the oxime moiety to point downward in direction to 3.40 at hH3R, than at 
rH3R. 
Additionally, Trp6.48 is shown in its active conformation at hH3R (Fig. 3.9, C, blue 
arrow) and in its inactive conformation at rH3R (Fig. 3.9, D, blue arrow). Trp
6.48 is part of a 
highly conserved motif among GPCRs, thought to function as a toggle-switch during receptor 
activation, as is evident due to structural and biophysical studies (Ahuja and Smith, 2009). 
Trp6.48 horizontal to the membrane surface stabilizes the active state of a GPCR. Trp6.48 
vertical to the membrane surface stabilizes the inactive state of a GPCR. As consequence of 
the different amino acids at position 3.37 and 3.40 between hH3R and rH3R, the oxime 
moiety of imoproxifan can establish a hydrogen bond interaction to Trp6.48 in its active 
conformation, thus stabilizing the active conformation of hH3R (Fig. 3.9, E, yellow, dotted 
line). This interaction was not found at rH3R. Here, the hydrogen of the oxime moiety 
interacts electrostatically with a negatively charged surface established by Glu5.46 and Tyr3.33 
(Fig. 3.9, F, yellow, dotted line). At rH3R, the methyl group of imoproxifan is located in a small 
pocket established by Val3.40 and Trp6.48 in its inactive conformation. 
Collectively, the different binding modes of imoproxifan at hH3R and rH3R presumably 
lead to differences in efficacies due to a different orientation of the oxime moiety and thus, 
stabilization of Trp6.48 either horizontal or vertical to the membrane surface. 
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3.5 Discussion 
 
 Ligand pharmacology at hH3R and rH3R is species-dependent. Unexpectedly, the 
species-differences can even span from agonism to inverse agonism in the case of 
imoproxifan. In this study, we unraveled the underlying molecular mechanism of this reversal 
in efficacy. In steady-state GTPase assays, imoproxifan was an inverse agonist at rH3R, but 
almost full agonist at hH3R. Competition binding studies with [
3H]NAMH confirmed that the 
effect was receptor-mediated. Both hH3R and rH3R were expressed at similar levels and 
defined receptor-to-G protein stoichiometries. The basal activity in the two systems was 
comparable, as indicated by the similar inhibitory effects of the standard inverse agonist 
thioperamide. Thus, the unexpected behaviour of imoproxifan can only be due to species-
specific differences in ligand recognition and receptor activation. Previous modelling studies 
described the binding mode of FUB181, a compound, similar to imoproxifan (Schlegel et al., 
2007). The orientation of imoproxifan in the binding pocket of H3R, determined in the present 
study, is similar to these previous findings. In another study, it was suggested, that the 
Ala3.40Val amino acid difference between hH3R and rH3R is responsible for the observed 
species-differences in antagonist pharmacology (Yao et al., 2003). It was pointed out that 
thioperamide or compound A-304121 are in closer contact to Val3.40 at rH3R, than to Ala
3.40 at 
hH3R. We could reproduce this finding because the affinity and potency of thioperamide was 
higher at rH3R than hH3R in our experimental system, too. Our molecular modelling studies 
further revealed that both amino acid differences in TM III, at position 3.37 and 3.40, are 
responsible for the differences in pharmacology of imoproxifan between hH3R and rH3R. 
Because of the lacking negative surface potential between TM V and TM III, the oxime 
moiety points downward in direction of Ala3.40 at hH3R. Thus, the polar oxime moiety is able 
to establish a hydrogen bond interaction to Trp6.48 in its active conformation. In contrast, at 
rH3R, the negatively charged surface of the binding pocket between TM V and TM III allows 
the oxime moiety to point upward. Additionally, the methyl moiety of imoproxifan fits optimally 
into a small pocket between the bulky Val3.40 and Trp6.48 in its inactive conformation. The 
highly conserved Trp6.48 is suggested to act as a switch for receptor activation within biogenic 
amine receptors. Trp6.48 horizontal to the membrane surface is thought to stabilize the active 
state of a receptor, while Trp6.48 vertical to the membrane surface stabilizes the inactive state 
of a receptor. Since the hydrogen bond interaction between the oxime moiety and Trp6.48 
stabilizes Trp6.48 in its active conformation at hH3R, the partial agonism of imoproxifan is 
explained on a molecular level. This hydrogen bond-supported stabilization of Trp6.48 in its 
active conformation is not possible at rH3R. Here, in contrast to hH3R, the methyl group near 
Val3.40 and Trp6.48 stabilizes Trp6.48 in its inactive conformation due to a hydrophobic 
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interaction. Thus, the modelling studies provide an explanation for the inverse agonism of 
imoproxifan at rH3R on a molecular level, too. 
Interestingly, the pKi values imoproxifan (7) at hH3R and rH3R were significantly 
higher than their pEC50 values (t test, p < 0.05). These results suggest that hH3R and rH3R 
can exist in a state of low partial agonist/inverse agonist affinity that interacts efficiently with 
G proteins. Another study, analyzing the hH3R expressed in SK-N-MC cells by [
3H]NAMH 
competition binding and CRE-β-galactosidase reporter gene assays, revealed similar 
disparities (Lim et al., 2005). Similar results were also obtained when the human formyl 
peptide receptor, coupled to various Gi-proteins, was studied in Sf9 cell membranes 
(Wenzel-Seifert et al., 1999). In this study, the Kd of the agonist radioligand [
3H]fMLP is ~100-
fold lower than the EC50 determined in GTPase experiments. Interestingly, at hH3R 
expressed in Sf9 cells the low affinity state stabilized by imoproxifan (7) leads to an activation 
of G proteins, whereas at rH3R the low affinity state inhibits the activation of G proteins. 
The G protein coupling profile hH3R and rH3R was similar, too (Table 3.2; Schnell et 
al., 2009). An important fact is that like for hH3R (Schnell et al., 2009), at rH3R no evidence 
for functional selectivity was observed (Table 3.3). Both hH3R and rH3R coupled effectively 
with Gi/Go-proteins in Sf9 cell membranes, as was shown by GTPγS-sensitive ternary 
complex formation, using [3H]NAMH as radioligand, and steady-state [γ-32P]GTP hydrolysis. 
The similarly small shifts of the [3H]NAMH saturation binding curves at hH3R and rH3R by 
GTPγS indicate a similarly strong interaction of both receptors with the G protein and are in 
line with the high constitutive activity of the H3Rs. Thus, the results confirm the data of the 
GTPase experiments. Similar constitutive activity renders the system well suited for the 
analysis of species-specific ligand effects, since differences in constitutive activity between 
GPCRs can alter their pharmacological profiles and lead to a further complication of data 
interpretation (Preuss et al., 2007a, b). 
The pharmacology of all histamine receptors (HxRs) is species-dependent. This is 
especially true for HxR agonists. At the H1R, several classes of bulky ligands exhibit species 
differences (Seifert et al., 2003). Some of them show unique behaviours, like epimeric 
members of the ergoline family or chiral histaprodifens, switching from silent antagonism to 
partial agonism depending on the species studied (Pertz et al., 2006; Strasser et al., 2008a). 
Detailed molecular studies dissected some of the underlying mechanisms (Strasser et al., 
2008b; Strasser et al., 2009). At the H2R, bulky agonists like the long-chained impromidine- 
and arpromidine-derived guanidines or NG-acylated imidazolylpropylguanidines (AIPGs), are 
more potent and efficacious at the gpH2R than at the hH2R (Kelley et al., 2001; Preuss et al., 
2007b). Metiamide was identified to be an inverse agonist at the hH2R, gpH2R and rH2R, but 
a weak partial agonist at the cH2R (Preuss et al., 2007a). At the H4R, which has the lowest 
sequence similarity between species, studies focusing on ligand-receptor interactions of 
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agonists are beginning to emerge (Lim et al., 2008; Igel et al., 2009). However, the species-
differences of imoproxifan at hH3R and rH3R described in this study represent the most 
substantial differences in pharmacology among HXRs identified so far. This is particularly 
compelling in view of the fact that hH3R and rH3R sequences display a high degree of 
homology and only two amino acid residues cause the disparities. 
 In conclusion, we have shown that hH3R and rH3R expressed in Sf9 cells both 
similarly couple to defined Gi/Go-protein heterotrimers and display similar constitutive 
activities. We show species-differences in pharmacological properties of imoproxifan and 
offer an explanation on the molecular basis for these differences. Most importantly, we 
introduce novel active state models of hH3R and rH3R that are suitable to explain the efficacy 
of H3R ligands. 
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4.1 Abstract 
 
Monovalent ions differently affect ligand binding to G protein-coupled receptors 
(GPCRs) by as yet poorly defined mechanisms. In particular, NaCl often decreases the 
affinity of agonists but increases it for antagonists. We examined the effect of various 
monovalent ions on human histamine H3 receptor (hH3R), co-expressed with mammalian G 
proteins (Gαi1, Gαi2, Gαi3 or Gαo1, and β1γ2 dimers, respectively) in Sf9 insect cell membranes, 
with respect to agonist binding and G protein activation. NaCl (100 mM) had no effect on 
affinity of the agonist [3H]Nα-methylhistamine ([3H]NAMH). In steady-state GTPase assays, 
the endogenous agonist histamine had a lower potency and the inverse agonist thioperamide 
had a higher potency, when NaCl (100 mM) was present. Monovalent ions reduced H3R-
regulated signalling in the order of efficacy Li+ ~ Na+ ~ K+ < Cl- < Br- < I-. NaCl had a stronger 
effect on basal hH3R signalling when Gαi3 was co-expressed. Asp80
2.50, a putative interaction 
site for Na+, was mutated to Asn802.50 (D2.50N-hH3R). Strikingly, the mutation was unable to 
activate Gαi3 at all. The effects can be explained by a model, where (i) monovalent ions as 
well as a charge-neutralizing mutation of Asp802.50 generally reduce the interaction of hH3R 
with G proteins, (ii) monovalent anions increase the affinity of G proteins for GDP and thus, 
indirectly affect their interaction with hH3R and, (iii) Asp80
2.50 is a key residue for hH3R/Gαi3 
protein-activation. The latter result suggests that hH3R/G protein-coupling interfaces may 
differ even between closely related subunits. 
 
 
4.2 Introduction 
 
Histamine (HA) is an important local mediator and neurotransmitter (Haas et al., 
2008). All four histamine receptor subtypes (H1-4Rs) are expressed on neuronal cells. The 
histamine H3 receptor (H3R) is a Gi/Go-coupled presynaptic auto- and heteroreceptor, 
regulating the release of histamine and various other neurotransmitters via negative 
feedback mechanisms. The H3R is a promising drug target, because it participates in 
important physiological processes like the sleep-wake cycle, eating behaviour and cognition 
(Leurs et al., 2005). The H3R displays ligand-independent activity in many experimental 
systems (Arrang et al., 2007). It is also one of the few GPCRs for which constitutive activity 
has been demonstrated in vivo (Morisset et al., 2000). The concept of constitutive GPCR 
activity can be described by a two-state model, assuming that GPCRs isomerize between an 
inactive state (R) and an active state (R*), with agonists stabilizing the R* state and inverse 
agonists stabilizing the R state (Seifert and Wenzel-Seifert, 2002; 2003). 
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Fig. 4.1. The two state model of GPCR activation. GPCRs are able to isomerize from an 
inactive state (R) to an active state (R*). Ligands are classified according to their capability of 
shifting the equilibrium to either side of both states. Na+ - ions act as universal allosteric 
modulators at many GPCRs, stabilizing the inactive state (R). 
 
Na+ - ions act as allosteric stabilizers of the R state of many GPCRs (Seifert and 
Wenzel-Seifert, 2001; 2003) (Fig. 4.1). Recently, we have shown that the hH3R displays high 
constitutive activity when expressed in Sf9 insect cells (Schnell et al., 2009), like the 
structurally related hH4R (Schneider et al., 2009). This basal receptor activity can be 
suppressed by increasing NaCl concentrations. However, it is not clear if this effect is 
mediated by the cation or anion. Additionally, it is not clear if monovalent ions bind to the 
receptor or the coupling G protein. In this study, we investigated the effect of different 
monovalent ions on hH3R coupled to Gi/Go proteins. Moreover, we mutated Asp80
2.50, a 
highly conserved amino acid among GPCRs, thought to be a binding site for Na+ - ions 
(Horstman et al., 1990) (Fig. 4.2). 
 
Chapter 4: Modulation of H3R function by monovalent ions 
 
99 
 
 
Fig. 4.2. Snake representation of the human H3R. The red arrow points towards the highly 
conserved Asp802.50, which was mutated to Asn802.50. Residues within TM domains are 
named according to the Ballesteros/Weinstein nomenclature. The most conserved residue in 
each TM is numbered as X.50, where X is the number of the respective TM domain 
(Ballesteros and Weinstein, 1995). 
 
4.3 Materials and Methods 
 
The cDNA of the hH3R was kindly provided by Dr. T. Lovenberg (Johnson & Johnson 
Pharmaceutical R&D, San Diego, CA, USA). Reagents for molecular biology, recombinant 
baculoviruses encoding mammalian G protein subunits, and the sources of ligands were 
described before (Schnell et al., 2009). Pfu Ultra II Fusion HS DNA polymerase was obtained 
from Stratagene (La Jolla, CA, USA). Stock solutions (10 mM) of all H3R ligands described in 
this paper were prepared in distilled water and stored at -20°C. [3H]NAMH (74-85 Ci/mmol) 
was obtained from Perkin Elmer (Boston, MA, USA). [γ-32P]GTP was synthesized as 
described (Schnell et al., 2009). Unlabeled nucleotides were from Roche (Indianapolis, IN, 
USA) and inorganic salts as well as all other reagents were of the highest purity available 
and from standard suppliers. 
The cDNA for the mutated construct was generated using the QuickChange Site-
Directed Mutagenesis Kit (Stratagene), with pVL1392-3Z-SF-hH3R-His6 as template (Schnell 
et al., 2009). As primers, D2.50N-fwd (5´-CTG CTC AAC CTC GCC ATC TCC AAC TTC 
CTC GTC GGA GCC TTC TGC-3´) and D2.50N-rev (5´-GCA GAA GGC TCC GAC GAG 
GAA GTT GGA GAT GGC GAG GTTG AGC AG-3´) were used, including a codon 
introducing the mutation and a silent mutation for a diagnostic restriction site (Mme I). The 
Chapter 4: Modulation of H3R function by monovalent ions 
 
100 
product was verified by restriction digestion and sequencing. The procedures for the 
generation of recombinant baculoviruses, Sf9 insect cell culture and membrane preparation, 
SDS-PAGE and immunoblot analysis were described before (Schnell et al., 2009). 
Essentially, [³H]NAMH binding experiments were performed as described in (Schnell 
et al., 2009). Each reaction tube contained 40 µg of protein. Non-specific binding was 
determined in the presence of [3H]NAMH at various concentrations plus 10 µM thioperamide 
and amounted to <10% of total binding at saturating concentrations. Incubations were 
conducted for 60 min at RT and shaking at 250 rpm. Experiments were carried out using 0.3 
to 5 (10) nM final [3H]NAMH. Bound [3H]NAMH was separated from free [3H]NAMH by 
filtration through 0.3% (m/v) polyethyleneimine-pretreated GF/C filters, followed by three 
washes with 2 ml of binding buffer (4°C). Filter-bound radioactivity was determined by liquid 
scintillation counting. The experimental conditions chosen ensured that not more than 10 % 
of the total amount of radioactivity added to binding tubes was bound to filters. 
Steady-state GTPase activity experiments were also performed in analogy to the 
assays described in (Schnell et al., 2009). Briefly, assay tubes contained Sf9 membranes (20 
µg of protein/tube), 5.0 mM MgCl2, 0.1 mM EDTA, 0.1 mM ATP, 100 nM GTP, 0.1 mM 
adenylyl imidodiphosphate, 1.2 mM creatine phosphate, 1 µg of creatine kinase, and 0.2% 
(w/v) bovine serum albumin in 50 mM Tris/HCl, pH 7.4, and H3R ligands at various 
concentrations. Reaction mixtures (80 µl) were incubated for 2 min at 25°C before the 
addition of 20 µl of [γ-32P]GTP (0.1 µCi/tube). All stock and work dilutions of [γ-32P]GTP were 
prepared in 20 mM Tris/HCl, pH 7.4. Reactions were conducted for 20 min at 25°C. 
Reactions were terminated by the addition of 900 µl of slurry consisting of 5% (m/v) activated 
charcoal and 50 mM NaH2PO4, pH 2.0. Charcoal absorbs nucleotides but not Pi. Charcoal-
quenched reaction mixtures were centrifuged for 7 min at room temperature at 15,000g. Six 
hundred microliters of the supernatant fluid of reaction mixtures were removed, and 32Pi was 
determined by liquid scintillation counting. Enzyme activities were corrected for spontaneous 
degradation of [γ-32P]GTP. Spontaneous [γ-32P]GTP degradation was determined in tubes 
containing all of the above described components plus a very high concentration of 
unlabeled GTP (1 mM) that, by competition with [γ-32P]GTP, prevents [γ-32P]GTP hydrolysis 
by enzymatic activities present in Sf9 membranes. Spontaneous [γ-32P]GTP degradation was 
<1% of the total amount of radioactivity added using 20 mM Tris/HCl, pH 7.4, as solvent for 
[γ-32P]GTP. The experimental conditions chosen ensured that not more than 10% of the total 
amount of [γ-32P]GTP added was converted to 32Pi. 
 Molecular biology was planned with GCK 2.5 (Textco BioSoftware, West Lebanon, 
NH, USA), protein was determined using the DC protein assay kit (Bio-Rad, Hercules, CA, 
USA) and all analyses of experimental data were performed with the Prism 5 program 
(GraphPad Software, San Diego, CA, USA). 
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4.4 Results 
 
 We determined binding parameters of the agonist radioligand [3H]NAMH in Sf9 cell 
membranes co-expressing hH3R, Gαi2 and β1γ2 dimers in parallel in the absence and 
presence of NaCl (100 mM) (Fig. 4.3A). Unexpectedly, NaCl did not affect the affinity of 
[3H]NAMH at hH3R, but increased the number of binding sites. In the absence of NaCl, the 
Kd-value was 0.60 ± 0.07 nM (S. E. M., n = 3) and the Bmax-value was 0.62 ± 0.02 pmol/mg 
(S. E. M., n = 3). In the presence of NaCl (100 mM), [3H]NAMH bound to the hH3R with a Kd 
of 0.74 ± 0.06 nM (S. E. M., n = 3) and a Bmax of 0.85 ± 0.02 pmol/mg (S. E. M., n = 3). This 
is surprising, because classically NaCl decreases the affinity of agonists at GPCRs (Limbird 
et al., 1982; Neve et al., 1990). 
 
 
 
 
 
 
 
 
 
Fig. 4.3. The effect of NaCl on high-affinity agonist binding and steady-state GTP 
hydrolysis in Sf9 cell membranes expressing hH3R in combination with Gαi2 and β1γ2. 
Experiments were performed as described under Materials and Methods. In A, reaction 
tubes contained membranes and [3H]NAMH in concentrations indicated on the abscissa. 
Nonspecific binding was determined in the presence of THIO (10 µM). Data were analyzed 
by nonlinear regression and were best fitted to hyperbolic one-site saturation isotherms. The 
closed circles (●) show the data for specific [3H]NAMH binding in the absence of NaCl, the 
open circles (○) in the presence of NaCl (100 mM). Data points shown are the means ± S. E. 
M. of 3 independent experiments performed in duplicate. Data are expressed as percentage 
change of specific [3H]NAMH binding in the presence of NaCl (100 mM) compared to the 
binding in the absence of NaCl, which was defined to be 100%. In B, reaction mixtures 
contained HA or THIO at the concentrations indicated on the abscissa to achieve saturation. 
Data were analyzed by nonlinear regression and were best fitted to sigmoidal 
concentration/response curves. Data are expressed as percentage change in GTPase 
activity induced by the ligands compared to the GTPase activity stimulated by HA (10 µM) in 
the absence of NaCl, which was defined to be 100%. The closed symbols show data in the 
absence of NaCl, the open symbols data in the presence of NaCl (100 mM). Data points 
shown are the means ± S. E. M. of 3 independent experiments performed in duplicate. 
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 However, in steady-state GTPase assays the pEC50-value of the endogenous agonist 
histamine (HA) (8.01 ± 0.39, S. E. M., n = 3) was decreased to 7.53 ± 0.18 (S. E. M., n = 3) in 
the presence of NaCl (100 mM) (Fig. 4.3B). In contrast, the pEC50 of the inverse agonist 
thioperamide (THIO) (7.15 ± 0.31, S. E. M., n = 3) was increased to 7.43 ± 0.28 (S. E. M., n = 
3) in the presence of NaCl (100 mM) (Fig. 4.3B), indicating a reduced constitutive activity of 
the system. This result is in line with a lower basal hH3R-activity and efficacy of THIO in the 
presence of NaCl. Additionally, NaCl also enhanced the efficacy of HA at hH3R. Collectively, 
these functional data are in accordance with the two-state model of GPCR-activation (Seifert 
and Wenzel-Seifert, 2002; Seifert and Wenzel-Seifert, 2003). Thus, NaCl stabilizes the R-
state of hH3R. The NaCl-insensitivity of [
3H]NAMH-binding could be due to the very high 
constitutive activity of hH3R. At the structurally related hH4R, which shows even higher 
constitutive activity, NaCl has no effect on basal activity at all (Schneider et al., 2009). 
 Still, at the hH3R, it was not clear whether Na
+ or Cl- caused the effect on constitutive 
activity. Therefore, we examined the effect of different salts of monovalent ions with varying 
radii on hH3R-activity in the steady-state GTPase assay (Fig. 4.4). Monovalent ions reduced 
hH3R-regulated signalling in the order of efficacy Li
+ ~ Na+ ~ K+ < Cl- < Br- < I-. Especially, 
basal hH3R-signalling was more effectively reduced by salts of monovalent anions with 
greater radii. 
Chapter 4: Modulation of H3R function by monovalent ions 
 
103 
0 30 60 90 120 150
0
2
4
6
8
10
LiCl (mM)
G
T
P
 h
yd
ro
ly
s
is
(p
m
o
l
×
 m
g
-1
×
 m
in
-1
)
0 30 60 90 120 150
0
2
4
6
8
10
NaCl (mM)
G
T
P
 h
yd
ro
ly
s
is
(p
m
o
l
×
 m
g
-1
×
 m
in
-1
)
0 30 60 90 120 150
0
2
4
6
8
10
KCl (mM)
G
T
P
 h
yd
ro
ly
s
is
(p
m
o
l
×
 m
g
-1
×
 m
in
-1
)
0 30 60 90 120 150
0
2
4
6
8
10
LiBr (mM)
G
T
P
 h
yd
ro
ly
s
is
(p
m
o
l
×
 m
g
-1
×
 m
in
-1
)
0 30 60 90 120 150
0
2
4
6
8
10
NaBr (mM)
G
T
P
 h
yd
ro
ly
s
is
(p
m
o
l
×
 m
g
-1
×
 m
in
-1
)
0 30 60 90 120 150
0
2
4
6
8
10
KBr (mM)
G
T
P
 h
yd
ro
ly
s
is
(p
m
o
l
×
 m
g
-1
×
 m
in
-1
)
0 30 60 90 120 150
0
2
4
6
8
10
LiI (mM)
G
T
P
 h
yd
ro
ly
s
is
(p
m
o
l
×
 m
g
-1
×
 m
in
-1
)
0 30 60 90 120 150
0
2
4
6
8
10
NaI (mM)
G
T
P
 h
yd
ro
ly
s
is
(p
m
o
l
×
 m
g
-1
×
 m
in
-1
)
0 30 60 90 120 150
0
2
4
6
8
10
HA (10 µM)
basal
THIO (10 µM)
KI (mM)
G
T
P
 h
yd
ro
ly
s
is
(p
m
o
l
×
 m
g
-1
×
 m
in
-1
)
 
 
Fig. 4.4. Regulation of HA-, basal and THIO-regulated GTPase activity by different salts 
of monovalent ions. GTPase experiments were performed as described under Materials 
and Methods. Reaction mixtures contained Sf9 cell membranes expressing hH3R plus Gαi2 
plus β1γ2, HA (10 µM), ddH2O (basal) or THIO (10 µM) and salts in concentrations indicated 
on the abscissa. Data points shown are the means ± S. E. M. of 3 – 4 independent 
experiments performed in duplicate. 
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To find out which protein is modulated, we also tested the effect of NaCl on hH3R 
coupled to different Gi/Go-proteins. Interestingly, NaCl had a stronger effect on basal hH3R-
signalling when Gαi3 was co-expressed (Fig. 4.5). 
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Fig. 4.5. Regulation of HA-, basal and THIO-regulated GTPase activity by NaCl in the 
presence of different Gi/Go-proteins. GTPase experiments were performed as described 
under Materials and Methods. Reaction mixtures contained Sf9 cell membranes expressing 
hH3R plus mammalian G proteins (Gαi1, Gαi2, Gαi3 or Gαo1, and β1γ2 dimers, respectively), HA 
(10 µM), ddH2O (basal) or THIO (10 µM) and NaCl in concentrations indicated on the 
abscissa. Data points shown are the means ± S. E. M. of 3 independent experiments 
performed in duplicate. 
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In addition, we mutated Asp802.50, a highly conserved amino acid residue among 
GPCRs thought to act as a binding site for Na+ [4] (Horstman et al., 1990), to Asn802.50 
(D2.50N-hH3R). This charge-neutralizing point-mutation decreased the affinity of [
3H]NAMH 
at hH3R about 10-fold (Kd = 5.09 ± 1.11 nM, S. E. M., n = 3) (Fig. 4.6A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.6. The effect of Asp802.50→Asn802.50 mutation (D2.50N-hH3R) on high-affinity 
agonist binding and steady-state GTP hydrolysis in Sf9 cell membranes expressing 
the mutant in combination with Gαi2 and β1γ2. Experiments were performed as described 
under Materials and Methods. In A, reaction tubes contained membranes and [3H]NAMH in 
concentrations indicated on the abscissa. Nonspecific binding was determined in the 
presence of THIO (10 µM). Data were analyzed by nonlinear regression and were best fitted 
to a hyperbolic one-site saturation isotherm. Data points shown are the means ± S. E. M. of 3 
independent experiments performed in duplicate. The dotted line indicates the Bmax value of 
[3H]NAMH binding at the wild-type hH3R, co-expressed with Gαi2 and β1γ2, which was defined 
to be 100%. In B, reaction mixtures contained membranes, HA (10 µM), ddH2O (basal) or 
THIO (10 µM) and NaCl at concentrations indicated on the abscissa. Data points shown are 
the means ± S. E. M. of 3 independent experiments performed in duplicate. 
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The experiments were performed in parallel with wild-type hH3R in the absence of 
NaCl (Fig. 4.3A). Compared to the wild-type hH3R (Bmax = 100 %, per definition), D2.50N-
hH3R displayed a substantially lower number of binding sites for [
3H]NAMH (Bmax = 43.2 ± 4.6 
%) (Fig. 4.6A). In the steady-state GTPase assay, D2.50N-hH3R was not constitutively 
active, as indicated by the absent inhibitory effect of NaCl and the inverse agonist THIO (Fig. 
4.6B). 
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Fig. 4.7. The G-protein coupling profile of D2.50N-hH3R. Experiments were performed as 
described under Materials and Methods. Reaction mixtures contained membranes co-
expressing D2.50N-hH3R and mammalian G proteins (Gαi1, Gαi2, Gαi3 or Gαo1, and β1γ2 
dimers, respectively), HA (10 µM), ddH2O (basal) or THIO (10 µM). Data points shown are 
the means ± S. E. M. of 3 independent experiments performed in duplicate. 
 
 
Chapter 4: Modulation of H3R function by monovalent ions 
 
107 
However, NaCl had a strong inhibitory effect on HA-regulated GTPase. At 
concentrations above 90 mM, D2.50N-hH3R was completely inactive. Most strikingly, the 
mutation was unable to activate Gαi3 at all (Fig. 4.7), suggesting a key role of Asp80
2.50 and 
Na+ in hH3R/Gαi3-interaction. 
 
 
4.5 Discussion 
 
 We systematically studied the effect of NaCl on hH3R coupled to various Gi/Go-
proteins. Surprisingly, NaCl preferentially abolished constitutive signalling through Gαi3. Most 
interestingly, a charge-neutralizing mutation of Asp802.50, thought to be an interaction site of 
Na+ - ions (Horstman et al., 1990), rendered hH3R unable to couple to Gαi3 at all. First of all, 
these findings indicate that Asp802.50 is crucial for Gαi3-coupling, but not for activation of other 
G-proteins. Although constitutive signalling of D2.50N-hH3R was abolished, the mutation was 
still able to activate the other G-proteins co-expressed. The data also point to a role of 
Asp802.50 as an interaction site for Na+ - ions, since the mutation partially mimicked the 
effects of high NaCl concentrations with respect to a suppression of constitutive signalling. 
However, the effects of high NaCl concentrations and mutation of Asp802.50 were not exactly 
the same and depended on the type of G-protein co-expressed. Additionally, high NaCl 
concentrations in combination with a charge-neutralizing mutation of Asp802.50 completely 
abolished the activity of hH3R in every case, indicating a more complex interaction of ions 
with hH3R and/or Gi/Go-proteins. If only an Asp80
2.50/Na+-interaction had played a role, the 
mutation would have been NaCl-insensitive. Thus, there is no definitive evidence of an 
Asp802.50/Na+-interaction. Nevertheless, the results indicate that the hH3R/Gαi3-protein 
coupling interface is unique and different compared to the other ones. 
It must be noticed that a mutation of Asp802.50 may also substantially influence the 
expression or proper folding of hH3R, since it causes a marked reduction of [
3H]NAMH 
binding sites. This could have lead to a general reduction in G-protein interaction. Similar 
results were obtained, when the α2A-adrenoceptor (α2AAR), another prototypical Gi/Go-
coupled receptor, was mutated at Asp792.50. It was shown that the point-mutated α2AAR 
(Asp792.50→Asn792.50) could signal through adenylyl cyclase and Ca2+-channels, but not K+-
channels, suggesting a differential G-protein coupling profile of the mutant (Surprenant et al., 
1992). Transgenic mice carrying this mutation showed characteristics very similar to α2AAR 
knock-out mice, because the mutation markedly reduced the expression of the receptor 
(MacMillan et al., 1998). These mice could not be used to study biased K+-channel signalling 
of α2AAR in vivo. A following study using receptor-Gαi fusion proteins then clearly showed that 
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the mutation leads to a general reduction of GTP turnover and not to G protein selectivity 
(Ward and Milligan, 1999). 
 We also systematically tested the effect of different monovalent ions on hH3R activity. 
Here, interestingly halides of increasing radii showed more prominent effects on constitutive 
and agonist-mediated hH3R activity, suggesting that it is not the cation, but the anion, 
causing a decrease in hH3R signalling. Similar effects were shown when the hβ2AR fused to 
the long splice-variant of Gαs (GαsL) was studied (Seifert, 2001). The effects were explained 
by a model, where anions increase the affinity of GDP for the G-protein and thereby 
decrease the efficiency of the agonist-free and agonist-occupied hβ2AR at promoting GDP 
dissociation from GαsL. Similar effects were also observed when the human chemokine 
receptor CXCR4 was studied in Sf9 cell membranes (Kleemann et al., 2008). In accordance 
with the model, Cl- anions decrease GDP dissociation from purified Gαo (Higashijima et al., 
1987). By analogy, halides could increase the GDP-affinity of other Gi/Go-proteins, thereby 
rendering GDP/GTP-exchange less efficient. Moreover, halides could differentially alter the 
GDP-affinity of specific Gi/Go-proteins, which would be an alternative explanation for G-
protein specificity found for hH3R. Additionally, salts could interfere with the ligand binding 
process. 
Collectively, we have shown that salts differently modulate hH3R Gi/Go-protein 
interaction. However, the underlying mechanisms are complex. Regardless of the specific 
mechanisms involved, from a practical perspective, the substantial impact of monovalent 
ions on hH3R-mediated Gi/Go-protein activation should be considered in future experiments. 
It is unknown, if there is any in vivo-relevance of the regulation of hH3R Gi/Go-protein 
interaction by monovalent anions and cations, but it is possible that (patho)physiological 
changes in intracellular Na+, K+ or Cl- concentrations could affect hH3R-signalling. Li
+, Br- and 
I- are of no physiological relevance and constitute only pharmacological tools. 
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5.1 Summary 
 
The histamine H3 receptor (H3R) is a biogenic amine receptor that belongs to family I 
of G protein-coupled receptors (GPCRs). During the past two decades, the H3R has gained 
much interest in academia and industry. The H3Rs is predominantly localized in the brain and 
regulates the release of histamine as well as other neurotransmitters into the synaptic cleft 
via negative feedback mechanisms. Thus, H3Rs serve as presynaptic auto- or 
heteroreceptors. H3Rs play an important role in processes like cognition and the sleep-wake-
cycle. Numerous ligands targeting H3R have been developed as pharmacological tools or 
potential therapeutics. Some of them show unexpected and pleiotropic effects. The currently 
available data are not sufficient to explain this uncommon behaviour. 
 The aim of this thesis was to investigate the detailed molecular mechanisms of some 
yet unexplained H3R-ligand effects. Therefore, sensitive baculovirus/Sf9 cell-based assay 
systems to analyze human H3R (hH3R) and rat H3R (rH3R) on a molecular level, were 
established. 
It is known that certain imidazole-containing H3R-ligands like proxyfan are functionally 
selective, i. e. activate only specific pathways mediated by H3R. In this work, the detailed G 
protein coupling-profile of H3R was investigated and various imidazole-based ligands were 
examined. We did not obtain evidence for differences in the G protein coupling profile of the 
H3R or functional selectivity of any of the compounds assayed. Possible reasons for the 
discrepancies between the results and data obtained from the literature are discussed. 
These “negative” results cannot be attributed to unsuitability of our expression system for 
exclusion of ligand functional selectivity. However, our system is not suitable to definitely 
exclude protean agonism, a special case of functional selectivity, at H3R, since that would 
require a systematic and precise variation of receptor-to-G protein stoichiometries. Extensive 
systematic studies under clearly defined experimental conditions are required to reconcile 
the discrepancies. Thus, presently, a specific and generally applicable mechanistic 
explanation for the previously observed pleiotropic effects of proxyfan cannot yet be 
provided. 
Additionally, despite a very high sequence homology of hH3R and rH3R, there are 
substantial pharmacological species differences. Imoproxifan is an inverse agonist at rH3R, 
but almost full agonist at hH3R. We have shown that hH3R and rH3R expressed in Sf9 cells 
both couple similarly to defined Gi/Go-protein heterotrimers and display similar constitutive 
activities. We show species-differences in pharmacological properties of imoproxifan and 
offer an explanation on the molecular basis for these differences. Most importantly, we 
introduce novel active state models of hH3R and rH3R that are suitable to explain the efficacy 
of H3R ligands. Two amino acid residues between hH3R and rH3R cause the reversal in 
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efficacy of imoproxifan due to substantial differences in the electrostatic potential surfaces of 
the binding pockets. 
Monovalent ions differentially affect GPCR signalling by as yet poorly understood 
mechanisms. In particular, Na+ is known as universal allosteric GPCR modulator. However, it 
is unknown how Na+ - ions exert the effects and whether it is not the counter-ion, which is 
responsible for the salt effects. Therefore, the H3R was used as a model system to study the 
effect of various monovalent ions. Moreover, a highly conserved aspartate in TM II, thought 
to be an interaction site of Na+ - ions in GPCRs, was mutated to asparagine. It turned out that 
most probably both, cation and anion, exert a modulatory effect on GPCR/G protein-
coupling. Monovalent cations may stabilize an inactive H3R-state via interaction with the 
conserved aspartate in TM II, while anions may increase the affinity of G proteins for GDP 
and thus, indirectly affect their interaction with H3R. Interestingly, NaCl differentially affects 
the G protein coupling-profile of H3R. NaCl selectively abolished constitutive signalling of H3R 
only in the presence of Gαi3. Obviously, the conserved aspartate in TM II is a key residue for 
H3R/Gαi3 protein-activation. The latter result suggests that H3R/G protein-coupling interfaces 
may differ even between closely related subunits. 
 In conclusion, this thesis provides new insight into the molecular mechanisms of H3R 
function, G protein-coupling and species-differences. The availability of a sensitive H3R test 
system will improve the development of new histamine receptor ligands, especially with 
respect to selectivity over the structurally related H4R, and contribute to a better 
understanding of ligand effects. Most importantly, a gap was filled regarding the interaction of 
H3R with specific G protein α-subunits, an until now insufficiently investigated area. 
 
 
5.2 Zusammenfassung 
 
Der Histamin H3-Rezeptor (H3R) gehört zur Superfamilie der G-Protein-gekoppelten 
Rezeptoren (GPCRs). Die Klonierung des H3R hat bei Wissenschaftlern im akademischen 
Bereich und in der Industrie großes Interesse geweckt. Der H3Rs wird hauptsächlich im 
Gehirn exprimiert und reguliert die Ausschüttung von Histamin und anderen 
Neurotransmittern in den synaptischen Spalt über negative Rückkopplungsmechanismen. 
H3Rs werden deshalb als präsynaptische Auto- oder auch Heterorezeptoren bezeichnet. 
H3Rs spielen eine wichtige Rolle bei kognitiven Prozessen und der Regulation des Schlaf-
Wach-Rhythmus. Viele H3R-Liganden wurden bereits entwickelt, entweder als 
pharmakologische Werkzeuge oder mögliche Therapeutika. Einige von diesen Substanzen 
zeigen unerwartete Effekte in verschiedenen pharmakologischen Testsystemen. Anhand 
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bisheriger Daten kann die ungewöhnliche Pharmakologie dieser Verbindungen aber nicht 
eindeutig erklärt werden. 
 Ziel dieser Arbeit war es, den detaillierten molekularen Aktivierungsmechanismus des 
H3R näher zu beschreiben. Zu diesem Zweck wurde ein sensitives, auf Bakuloviren und Sf9-
Zellen basierendes, Testsystem zur Analyse des humanen H3R (hH3R) und Ratten H3R 
(rH3R) auf molekularer Ebene, etabliert. 
Es ist bekannt, dass bestimmte imidazol-haltige H3R-Liganden, wie Proxyfan, 
funktionell selektiv sind, d. h. nur bestimmte H3R-vermittelte Signalwege aktivieren. Deshalb 
wurde in dieser Arbeit die Kopplung des H3R an verschiedene G-Proteine untersucht und 
eine Reihe von imidazol-haltigen Liganden getestet. Keine der Verbindungen war funktionell 
selektiv. Mögliche Ursachen für die Diskrepanzen zwischen diesen Ergebnissen und Daten 
aus der Literatur werden diskutiert. Diese „negativen“ Daten, welche gegen eine funktionelle 
Selektivität der untersuchten Substanzen sprechen, sind nicht auf das von uns entwickelte 
Testsystem zurückzuführen. Jedoch kann auf Grundlage dieser Daten „protean agonism“, 
eine spezielle Form von funktioneller Selektivität, nicht ausgeschlossen werden. Dazu 
müsste die Rezeptor/G-Protein-Stöchiometrie gezielt und systematisch verändert werden. 
Aufwändige Studien unter klar definierten experimentellen Bedingungen werden dafür in 
Zukunft notwendig sein. Zum jetzigen Zeitpunkt gibt es also noch keine zufriedenstellende 
Erklärung für die ungewöhnliche Pharmakologie von Proxyfan. 
Trotz einer hohen Sequenzhomologie zwischen hH3R und rH3R gibt es erhebliche 
pharmakologische Speziesunterschiede. Imoproxifan, ein inverser Agonist am rH3R, ist fast 
ein voller Agonist am hH3R. Wir konnten zeigen, dass hH3R und rH3R in Sf9-Zellen ähnlich 
gut an heterotrimere Gi/Go-Proteine koppeln und eine ähnlich hohe konstitutive Aktivität 
besitzen. Die molekulare Ursache für das Spezies-spezifische Verhalten von Imoproxifan 
wurde aufgeklärt. Dafür wurden neue und bisher nicht verfügbare Computermodelle des 
aktiven Zustandes von hH3R und rH3R generiert. Unterschiede in nur zwei Aminosäuren 
zwischen hH3R und rH3R führen zu den pharmakologischen Unterschieden aufgrund 
unterschiedlicher elektrostatischer Oberflächenpotentiale der Bindetaschen. 
 Monovalente Ionen beeinflussen die GPCR-Signaltransduktion auf verschiedene Art 
und Weise. Die zugrunde liegenden Mechanismen werden aber nur wenig verstanden. 
Natriumionen sind universelle allosterische GPCR-Modulatoren. Wie Natriumionen aber 
diese Effekte verursachen, und ob nicht das Gegenion auch eine Rolle spielt, ist bisher 
allerdings nur unzureichend untersucht. Um sich dem Problem anzunähern, wurde der H3R 
als Modellsystem verwendet und die Effekte verschiedener Salze monovalenter Ionen 
studiert. Zusätzlich wurde ein hochkonserviertes Aspartat in TM II, welches eine potentielle 
Interaktionsstelle für Natriumionen in GPCRs darstellt, zu Asparagin mutiert. Aufgrund der 
vorliegenden Daten wird geschlussfolgert, dass wahrscheinlich sowohl Kationen als auch 
Chapter 5: Summary/Zusammenfassung 115 
Anionen die GPCR/G-Proteinkopplung modulieren. Monovalente Kationen stabilisieren einen 
inaktiven H3R-Zustand über eine Interaktion mit dem konservierten Aspartat in TM II, 
während Anionen die Affinität von G-Proteinen zu GDP erhöhen und daher indirekt deren 
Interaktion mit dem H3R beeinflussen. Interessanterweise beeinflusst NaCl die Kopplung des 
H3R an verschiedene G-Proteine auf unterschiedliche Art und Weise. NaCl unterdrückt 
selektiv die konstitutive Aktivität des H3R nur in Anwesenheit von Gαi3. Das konservierte 
Aspartat in TM II spielt bei der H3R/Gαi3-Interaktion eine Schlüsselrolle. Diese Daten 
suggerieren, dass die H3R/G-Proteininteraktionsflächen unterschiedlich sein müssen, sogar 
bei sehr nah verwandten Untereinheiten. 
 Zusammenfassend erbrachte diese Dissertation neue Einblicke in den molekularen 
Aktivierungsmechanismus des H3R und dessen G-Proteinkopplung. Außerdem wurden 
wichtige Speziesunterschiede auf molekularer Ebene geklärt. Die Verfügbarkeit eines 
sensitiven und robusten H3R-Testsystems ist eine wichtige Voraussetzung für die 
Entwicklung neuer selektiver Histamin-Rezeptorliganden, speziell gegenüber dem strukturell 
verwandten H4R, und zur Erlangung eines besseren Verständnisses von ungewöhnlichen 
Ligandeneffekten. 
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07/2005       Approbation als Apotheker 
 
06/2005       Abschluss der Pharmazeutischen Prüfung (3. Abschnitt) 
 
11/2004 – 05/2005 Apotheke der Barmherzigen Brüder, Nicolaus Weigl e. K. 
 
05/2004 – 10/2004 HEXAL Pharmaforschung GmbH 
 
 
Universitärer Werdegang 
 
04/2004 Abschluss: 2. Abschnitt der Pharmazeutischen Prüfung 
 
01/2001 – 04/2003 Studentischer Mitarbeiter, Chromeon GmbH 
 
11/1999 – 04/2004 Studium der Pharmazie, Universität Regensburg 
 
 
Wehrdienst  
 
07/1998 – 04/1999 Sanitätssoldat der Bundeswehr 
 
 
Schule  
 
06/1998 Abitur 
 
09/1989 – 05/1998 Descartes-Gymnasium Neuburg 
 
09/1985 – 07/1989 Grundschule Neuburg-Ost 
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03/2009 Advanced Courses in Pharmacology 
 Teil 1: Tiermodelle in der Pharmakologischen Forschung 
 Teil 2: Arzneimittelinteraktionen, -metabolismus und -transport 
 
04/2006 – 03/2007 Weiterbildung „Versuchstierkunde und Tierschutz“ 
 Bestandteil des Nachweises der Sachkunde für den Umgang  
 mit Versuchstieren (FELASA Kategorie B) innerhalb der EU 
 
04/2006 Fortbildungsveranstaltung für Projektleiter und Beauftragte  
 für Biologische Sicherheit (BBS) 
 Nach §15 und 17 der Gentechniksicherheitsverordnung 
 
 
 
A.4 Teilnahme an Austauschprogrammen 
 
 
2007 
 
RISE - Research Internships in Science and Engineering 
Deutscher Akademischer Austauschdienst (DAAD) 
Juni – August 2007 
 
 
2006 
 
RISE - Research Internships in Science and Engineering 
Deutscher Akademischer Austauschdienst (DAAD) 
Juni - August 2006 
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